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Abstract 
Recombinant proteins, produced by introducing DNA into producer cells, are important in biotechnology, 
pharmaceuticals and academia. While prokaryotic cells are still most commonly used in these fields, 
mammalian cells are becoming more prevalent, especially for human proteins such antibodies, due to 
their inherent ability to correctly fold proteins, and retroviral vectors, due to their viral pseudotyping.  
This dissertation focuses on engineering improvement of recombinant protein expression and retroviral 
vector titer using both intrinsic methods such as cell engineering and extrinsic methods such as process 
development. To this end, multiple strategies such as non-coding RNA, stable transfections, 
CRISPR/Cas9 knockout, high-throughput screenings, and bioreactor perfusion processes were employed. 
Retroviral vectors have been of interest for some time due to their ability to modify genomes with relative 
ease and safety. This is increasingly so with the advancement of adoptive T-cell therapy, which is the 
transfer of T-Cells into a patient. These T-cells, often autologous, are typically modified, via various 
methods including retroviral vectors. 
Using mir-22-3p, which improves recombinant protein production, the first strategy was to identify gene 
targets of this microRNA that also improve recombinant protein expression. A microarray analysis was 
followed by bioinformatics; combining the results of the microarray with the predicted microRNA targets 
and the results of a high-throughput siRNA screen. Finally, confirmation with siRNA was performed to 
identify a focus gene, HIPK1.  
The second strategy was to create stable, high producing, recombinant protein expressing cell lines. This 
was achieved with a stably over-expressing microRNA, mir-22, and with a stable knockout of the gene 
identified earlier, HIPK1.  
Another strategy involved improving retroviral vector titer from PG13 cells in a bioreactor. PG13 cells 
are anchorage-dependent stable producing retroviral packaging cells for which scale up is difficult. It was 
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achieved by attaching the PG13 cells to microcarriers, growing them in a suspension like environment in 
a continuous perfusion bioreactor.  
The dissertation wraps up with the method development of a high throughput RNAi screening assay to 
improve retroviral titer. The purpose of the screening is to identify microRNAs or siRNAs that affect 
vector titer. The design involves miniaturization, assay development and optimization for two 
transfections.  
Advisors: Dr. Michael J. Betenbaugh and Dr. Joseph Shiloach  
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Preface 
This dissertation consists of 6 chapters and is focused on improving the expression of recombinant 
proteins and retroviral vectors.  
Chapter 1 provides an introduction by way of reviewing the ongoing efforts of improving recombinant 
protein expression in mammalian cells using non-coding RNA. It focuses on the methods used to identify 
non-coding RNAs and their targets, that can be used to engineer improvement of protein production. This 
work has been published in Genes [1]. Permission for its use was granted by MDPI (Creative Commons 
Attribution License).  
Chapter 2 identifies a gene targeted by mir-22-3p that is also involved in improving recombinant 
expression in HEK293 cells. The contents of chapter 2 have been published in Biotechnology Journal [2]. 
Permission for its use was granted by John Wiley and Sons (license number 4365981410776).  
Chapter 3 furthers the findings of chapter 2 through the development of stable cell lines over expressing 
mir-22 and knocking out HIPK1 using the CRISPR/Cas9 system. This work is being prepared for 
publication. 
Chapter 4 introduces the topic of retroviral vectors and improving production through a continuous 
perfusion bioreactor process with microcarriers. This work has been published in Biochemical 
Engineering Journal [3]. Permission for use was granted by Elsevier (Creative Commons license, CC-BY-
NC- ND).  
Chapter 5 explores the design of a high throughput screen for using microRNA or siRNA as a tool to 
improve retroviral vector production for Adoptive T-cell Therapy. 
Chapter 6 concludes the dissertation and discusses future work. 
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Chapter 1 Introduction: Methods for using non-coding RNAs to 
improve recombinant protein expression in mammalian cells 
Abbreviations: CHO, Chinese hamster ovary; eGFP, Green Fluorescent Protein; HEK, Human 
embryonic kidney; IgG, Immunoglobulin G; mAb, monoclonal antibody; mir, microRNA; nc-
RNA, non-coding RNA; qRT-PCR, quantitative real-time polymerase chain reaction; SEAP, 
secreted alkaline phosphatase; shRNA, short hairpin RNA; siRNA, small interfering RNA 
1.1 Summary  
The ability to produce recombinant proteins by utilizing different “cell factories” revolutionized 
biotherapeutics, pharmaceuticals and academic research. Chinese hamster ovary (CHO) cells are 
the dominant industrial producer, especially for antibodies. Human embryonic kidney cells 
(HEK), while not as widely used as CHO cells, are used where CHO cells are unable to meet the 
needs for expression such as growth factors. Therefore, improving recombinant protein 
expression from mammalian cells is a priority, and continuing effort is being devoted to this 
topic. Non-coding RNAs are RNA segments that are not translated into a protein and often have a 
regulatory role. Since their discovery, major progress has been made towards understanding their 
functions. Non-coding RNAs have been investigated extensively in relation to disease, especially 
cancer, and recently they have also been used as a method for engineering cells to improve their 
protein expression capability. This chapter is a review of methods used to identify small non-
coding RNAs and their gene targets with the potential of improving recombinant protein 
expression in mammalian cell lines, provided as an introduction to the dissertation.  
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1.2 Introduction  
The ability to produce recombinant proteins by utilizing different “cell factories” revolutionized 
biotherapeutics, pharmaceuticals, and academia, and consequently influenced health care 
operations worldwide [4]. Proteins can be produced in different prokaryotes and eukaryotes such 
as bacteria, fungi, yeast, insects cells and mammalian cells [5]. Mammalian cells are most 
suitable for pharmaceutical purposes because of their ability to biosynthesize complex proteins 
and, therefore, are currently the preferred producers [6, 7]. Chinese hamster ovary (CHO) cells 
are the dominant industrial producer, especially for antibodies, since they are able to grow in 
chemically defined media in suspension, are resistant to viral infection, and secrete high quality 
protein with some post-translational modifications similar to those of the human proteins [8]. 
Therefore, improving recombinant protein expression from CHO cells is a priority and continuing 
effort is being devoted to this since the first therapeutic protein, human tissue plasminogen 
activator, was approved [9]. Approaches such as improving metabolism, glycosylation, anti-
apoptosis and pro-proliferation, molecular chaperones, and protein folding have been successfully 
implemented [10, 11]. Human embryonic kidney cells (HEK), while not as widely used as CHO 
cells, are used for purposes where CHO cells are unable to meet the needs, for example 
expression of membrane proteins, specific growth factors and isolated receptor channels [12]. 
Generally, since HEK cells are human cells, they are more suitable than non-human cell lines for 
producing recombinant human proteins with proper post-translation modifications associated with 
correct folding to produce a preferred product [12-16].  
Small non-coding RNAs are primarily short RNA segments that are not translated into a protein. 
Since their discovery, a great deal of progress has been made towards understanding their 
function [17-19]. The microRNA is an example of a small regulatory non-coding RNA that is 
approximately 22 nucleotides long in mature form [20]. The sequence includes a seed region that 
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can promiscuously bind to multiple mRNA molecules and most often represses them by initiating 
degradation or translation inhibition. Small interfering RNA (siRNA) and short hairpin RNA 
(shRNA) are other types of non-coding RNA molecules among many others [21]. Non-coding 
RNAs have been investigated extensively in relation to disease especially cancer, and recently 
have also been used as a method for engineering cells to improve protein expression [22, 23]. 
Several reviews have been published on the use of microRNA for optimizing protein expression 
from CHO cells. These reviews focused on using microRNAs to engineer process improvements, 
such as cell growth improvement and apoptosis reduction [23-27]. This chapter is a review, of the 
methods used to identify non-coding RNAs with the potential of improving recombinant protein 
expression in mammalian cell lines provided as an introduction to the dissertation.  
1.3 MicroRNA Screening tools 
MicroRNAs are currently the most frequently used non-coding RNA for improving CHO and 
HEK cell protein production capabilities. MicroRNAs can target multiple genes in the same 
pathway, making them good targets of a specific cell process, such as reducing apoptosis, leading 
to improved protein production [25]. Initial work was done in 2007 by Gammell et al. [28], 
profiling microRNAs of CHO-K1 suspension cells during batch culture, at two different 
temperatures using cross-species microRNA microarrays. Following this work, other 
investigators began researching the possibilities of using microRNAs to improve protein 
expression and multiple microRNAs were evaluated for expression of a range of recombinant 
proteins as described in the following sections. A variety of screening methods were utilized for 
identifying specific microRNAs and their targets that can potentially improve expression of 
proteins. These methods include using previously identified microRNAs, microarrays, microRNA 
screens and next generation sequencing (NGS) (See Table 1-1).  
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1.3.1 Utilization of previously identified microRNAs  
Several microRNAs that were previously identified to affect specific growth properties of 
mammalian cells were tested for their possible effects on improving the expression of 
recombinant proteins. For example, in 2015, Kelly et al. [29] made use of the knowledge that the 
mir-34 family has pro-apoptotic and anti-proliferative function. By transient transfection of mir-
34 mimics and a stable mir-34 sponge they tested the effect on expressing secreted alkaline 
phosphatase (SEAP) in CHO cells. These experiments showed that mir-34 had a negative effect 
on the SEAP productivity of the CHO cells and microRNAs could be selected as targets for 
improving protein expression based on their functions. 
Another study in 2015 [30] explored the effect of mir-23 on CHO cells producing SEAP based on 
the role of mir-23 in energy metabolism. CHO cells expressing SEAP, that were stably depleted 
of mir-23, demonstrated improved SEAP productivity at the transcriptional level. Further 
exploration looked at the mitochondrial function and proteomic analysis using LC-MS examined 
potential targets.  
1.3.2 Microarrays utilization 
Microarrays are chips containing probes for the purpose of detecting differentially expressed 
microRNAs or mRNA in an RNA extract [31]. Microarrays made it possible to engineer cells that 
target microRNAs expressed in specific culture conditions such as apoptosis or temperature 
shifts. Gammell et al. [28] were the first to explore the possibility of using human, mouse and rat 
microRNA probes in the microarray format for analyzing CHO-K1 microRNA expression. They 
compared the microRNA profiles of suspension culture at two different temperatures, using 
human cell lines as a reference. A quantitative real-time polymerase chain reaction (qRT-PCR) 
was used to validate 5 selected microRNAs. Two microRNAs, mir-21 and mir-24 were confirmed 
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as being differentially regulated between the two temperature conditions. The Cricetulus griseus 
cgr-miR-21 was then isolated and cloned. In 2008, Barron et al. [32] used Human TaqMan Array 
MicroRNA cards (TLDA) to detect microRNAs that were differentially expressed during 
temperature shift of CHO cells. By following this analysis with qRT-PCR and miR-mimic and 
anti-miR transfections, they were able to identify mir-7 as a target for increasing cell proliferation 
and improving productivity of secreted alkaline phosphatase (SEAP) from the CHO cells. 
Following the identification of mir-7 as a target, Meleady et al. [33] investigated its impact on the 
cell proteome by using LC-MS/MS. They found that ribosomal and histone proteins, which also 
regulate growth and proliferation, are significantly downregulated. Two genes in cell growth, 
stmn1, that encodes stathmin, and cat, that encodes catalase, were identified as possible direct 
targets of mir-7. The researchers later generated stable clones with a mir-7 sponge decoy that 
improved cell density, viability, and secreted protein in a fed batch culture [34].  
In 2009, microarrays designed to probe human and mouse microRNAs were used to identify 
differentially expressed microRNAs in different growth stages of HEK 293 cells grown in a 
bioreactor [35]. By using this approach, Koh et al. were able to identify 13 microRNAs that were 
upregulated and one that was down-regulated in the exponential phase compared with their 
expression in the stationary phase. These microRNAs were related to apoptosis, growth arrest and 
differentiation. The researchers speculated that the identified microRNAs could be used to control 
cell cycle regulation, enhancing cell growth of both HEK and CHO cells. 
Another example of utilizing microarray for microRNAs identification is the library search that 
was conducted for microRNAs that induce apoptosis [36]. Apoptosis was induced in CHO cells 
by exposing the culture to nutrient depleted media and the microRNAs expression profile was 
evaluated by using microarrays with mouse and rat microRNAs. Following cluster analysis mmu-
mir-446-5p was selected for follow-up with qPCR and transient transfection with anti-mir. 
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Bioinformatics was then used to identify targets for this microRNA and narrow the list to the 
following apoptosis related genes: bcl2l2, dad1, birc6, stat5a and smo. Druz et al. [37] then 
examined the time-dependent activation of mir-466h-5p, mir-669c and the Sfmbt2 gene following 
glucose deprivation-induced oxidative stress which caused inhibition of histone deacetylation in 
mouse cells. Next, stable inhibition of mmu-mir-446h-5p by expression of anti-mir-446h-5p was 
done and the resulting engineered CHO cell line demonstrated improved apoptosis resistance 
together with enhanced production of SEAP [38].  
In 2011, a microarray analysis of human, mouse and rat microRNAs was used successfully to 
compare the microRNA profile of two CHO cell lines producing IgG with parental DG44 cell 
line [39]. After selecting 16 microRNAs, Lin et al. [39] proceeded to validation with qRT-PCR of 
four IgG-producing lines with varying degrees of productivity. Following the qRT-PCR analysis 
of the effect of amplification with Methotrexate on the microRNA was explored as well as a 
comparison to CHO K1. Bioinformatics analysis was performed to identify predicted targets of 
the five selected differentially expressed microRNAs, mir-221, mir-222, mir-19a, let-7b and mir-
17. Target genes were found to be involved in cell cycle progression, cell proliferation, and gene 
expression.  
Both cross-species microRNA and mRNA gene expression microarrays were used by Maccani et 
al. in 2014 [40] to identify microRNA expression specific to high producing CHO cell lines and 
potential miRNA-mRNA interactions to understand the biological functions of the microRNAs. 
Human, mouse, and rat microRNAs were used to probe RNA extracts of five cell lines. These cell 
lines included high and low producing single-chain Fv-Fc fusion antibody cell lines, high and low 
producing Human Serum albumin cell lines, and a non-producing CHO cell line that are used to 
identify differentially expressed microRNAs. The 14 most significantly differentially expressed 
microRNAs were selected for qRT-PCR and 11, including mir-10b-5p, mir-21-5p, and mir-221-
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3p, were validated. A bioinformatics analysis was completed to identify biological functions of 
the microRNAs. Then, a CHO-K1 based mRNA microarray analysis was completed and potential 
microRNA-mRNA interactions were computed. For the 11 validated microRNAs, there were as 
few as zero negatively correlated, differentially expressed targets and as many as 46 [40].  
A similar approach was used to profile the effects of mild hypothermia on HELA and CHO cells 
in a study by Emmerling et al. [41]. Microarrays of human microRNA probes for HELA cells 
expressing a recombinant adeno-associated virus (rAAV) were compared at two temperature 
conditions. For the CHO DG44 cells, the microarrays consisted of probes against mouse, rat, and 
human microRNAs. These microarrays were used to compare antibody expressing CHO cell lines 
at two temperature conditions. The investigators followed the microarrays with transient 
transfection of mir-483 mimics. It was determined that mir-483 regulates recombinant antibody 
and viral vector production in both CHO and Hela Cells but is processed differently in the two 
species. Bioinformatics analysis identified potential targets, KANK4, PDK4, MAPK3, and 
CXCR4. 
In 2016, Klanert et al. [42] used microarrays consisting of cross-species microRNA from human, 
mouse, rat, and viral microRNA to identify microRNAs associated with growth rate in several 
types of CHO cell lines expressing different recombinant products. They collected samples from 
cultures grown in different vessels, such as shaker flasks and bioreactors, in different media 
compositions with and without serum, and in different growth phases such as exponential and 
stationary and analyzed the differential expression of microRNA by using microarrays. They 
identified 12 microRNAs, among them mir-222-3p, mir-23a-3p and mir-29a-3p appear to be 
associated with growth rate in multiple CHO cell lines. 
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1.3.3 microRNA library screen 
Another approach currently used for identifying specific microRNAs is screening microRNA 
mimic libraries. The screens are designed to identify microRNAs that improve specific cell 
properties such as protein expression, viability, and growth. In this approach, instead of altering 
conditions and measuring different microRNA expression, the microRNA library is tested and 
microRNAs that showed the desired effect are selected for further evaluation. A sample workflow 
for a microRNA screen based on a study by Xiao et al. [43] is shown in Figure 1-1. In a 96-well 
plate format, a murine microRNA mimic library screen of 1139 microRNAs was used to 
determine microRNAs that improve the titer and specific productivity of SEAP producing CHO 
cell line [44]. After selecting the mir-30 family as a possible target for improving the SEAP 
productivity, stably over-expressing clones with members of the mir-30 family were generated 
[44]. In a follow up work, using bioinformatics and reporter assays, Fischer et al. [45] were able 
to identify members of the ubiquitin pathway as putative targets of the mir-30 family. The same 
high-content screen was used later to identify redundancy in microRNA control of cellular 
pathways [46]. The screen previously described, was used by Fischer et al. in 2015 [47] to 
identify mir-2861 as a potential target, confirm its expression in CHO cells, and evaluate its effect 
on recombinant protein expression in CHO cells. Using CHO cells expressing SEAP, they both 
transiently and stably transfected the cells with mir-2861 and siRNA against HDAC5, and 
analyzed apoptosis, cell cycle distribution, and productivity. Additionally, the link between mir-
2861 and HDAC5 was examined. The screen was also used to identify mir-143 as an enhancer of 
productivity in CHO cells [48]. Schoellhorn et al. enhanced production by transiently and stably 
transfected SEAP and monoclonal antibody producing CHO cell lines with mir-143. 
Bioinformatics and qRT-PCR were used to identify that MAPK7 is affected by mir-143 and 
following this observation, they were able to improve specific productivity using a MAPK7 
knockdown. 
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A high throughput human microRNA mimic screen in 96-well plate format was conducted by 
Strotbek et al. [49] using CHO cell line producing IgG. The initial screen that included 879 
microRNAs was followed with a smaller scale validation screen composed of 9 microRNAs to 
test the expression of recombinant human serum albumin from CHO cells. Based on the 
screening, stable CHO-IgG cell lines over-expressing microRNAs were constructed. Cell lines 
with over-expression of individual miR-557 or mir-1287 had no impact on productivity while a 
stable cell line over-expressing both mir-557 and mir-1287 had increased specific productivity 
and overall yield in a fed batch culture compared with the parental cell line.  
A later study by Fischer et al. [50], with the microRNA screen from Strotbek et al., used mir-557 
to improve multiple antibody producing CHO cell lines including difficult to express proteins. 
The effect of mir-557 was tested by transient transfection in seven cell line conditions including 
selection system (glutamine synthetase deficient and DHFR deficient), molecule type (IgG 
antibody, bispecific antibody and bispecific antibody-scFv fusion), and expression level (high, 
medium, low, and very low). They then went on to generate stable mir-557 over-expressing CHO 
cell lines and used these for cell line development of easy to express and a difficult to express 
monoclonal antibody.  
The microRNA screening approach was also used to determine microRNAs that improve 
expression of neurotensin receptor in HEK 293 cells [43]. Following primary screen of 875 
microRNA mimics in a 384-well plate format, 10 candidates were selected and validated with 
transfections in a 12-well plate format. The top candidates were tested for their effect on 
expression of 2 additional proteins for selecting microRNAs applicable for multiple protein types, 
of which mir-22-3p was selected for further study [43]. Recently, Meyer et al. [51] screened for 
microRNAs that increase antibody expression from transiently transfected HEK 293 cells by co-
transfecting with plasmid containing the antibody with each of 875 microRNAs in the human 
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microRNA library using a 384-well format. They found that adding valproic acid along with mir-
337-5p or mir-26a-5p with transient transfection of the antibody improves the titer up to two-fold. 
They also showed that improved expression is protein dependent. 
1.3.4 Next Generation Sequencing  
Next generation sequencing (NGS) is an essential tool for “omics” studies and, therefore, has 
often been implemented in noncoding RNA analysis [52]. In 2011, Hackl et al. [53] used NGS to 
sequence the small RNA transcriptome of 6 CHO cell lines. They identified and annotated 
sequence information for conserved and novel CHO microRNAs, creating tools for further 
microRNA research. From the list of microRNAs obtained, Jadhav et al. [54] tested the effect of 
over-expression of four microRNAs in CHO cells expressing recombinant erythropoietin-Fc 
fusion (EpoFc) by transient transfections of miRNA expression plasmids. They screened for 
growth and production characteristics and selected mir-17 since it caused a 15.4% increase in 
growth rate and consequently increases final EpoFc titer. They also used qPCR to measure 
mRNA of known targets for mir-17, to show that the over-expression of the microRNA was 
enough to regulate the target genes. The work was followed by stable over-expression of mir-17 
in a CHO cell line expressing EpoFc. The result was 2-fold increase in specific productivity and 
3-fold increase in overall titer [55].  
In 2014, Loh et al. [56] used NGS to profile microRNA in high and low expressing monoclonal 
antibody CHO cell lines. They identified a cluster of microRNAs that were differentially 
expressed in the high and low expressing cell lines and proceeded to individually and in 
combination express mir-17, mir-19b, mir-20a and mir-92a. The highest clones showed 130-
140% increase in specific productivity and titer and that mir-17, mir-19b and mir-92a were 
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correlated with increased protein expression. The study was followed later by bioinformatics and 
reporter assays to identify insig1 as the gene target of mir-92a in CHO cells [57]. 
By utilizing the observation that osmotic shifts in the media affect cell performance, Pfizenmaier 
et al. [58] studied mRNA and microRNA profile because of osmotic changes. After inducing an 
osmotic shift, they were able, by using NGS techniques, to identify mRNA and microRNAs that 
were differentially expressed at the different osmotic conditions, they followed by identifying 
targets that provided additional energy for recombinant protein biosynthesis. They identified 
several gene expression changes but focused on microRNA changes related to cell cycle arrest 
and proliferation, selecting mir-183 for stable over expression, improving specific productivity.  
In another study based on knowledge of productivity changes as a result of culture conditions, 
Stiefel et al. [59] used NGS to follow biphasic fed-batch cultivation, profiling low, high and non-
producing CHO cells and investigating the effect of mild hypothermia. They identified 89 
microRNAs that were differentially expressed between the different conditions. They then did a 
follow up validation experiment with 19 of these microRNAs transfecting them into CHO cells, 
measuring the effect on protein production, cell growth, apoptosis, and necrosis. The study 
wrapped up using bioinformatics were used to identify target genes and relevant pathways that 
might be regulated. 
1.4 Bioinformatics methodologies 
Interpretation of the experimental results obtained from any of the methods described in section 
1.3 for the identification of specific microRNAs, genes and pathways cannot be done without 
specific bioinformatics tools. Web-databases and algorithms available for predicting mRNA 
targets of microRNA that have been used in the studies described in this review are summarized 
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in Table 1-2. Additional detail for the basis and use of these algorithms can be found in numerous 
reviews and therefore will not be described here [60-62].  
Identifying mRNA targets of identified microRNAs allows researchers to begin understanding the 
pathways and mechanisms that might be involved in improving recombinant protein expression 
[28-30, 32, 33, 35, 36, 39-41, 45, 46, 48, 50, 53, 54, 57-59]. In addition to detecting the mRNA-
microRNAs interactions, investigators performed additional bioinformatics research to identify 
biological processes, gene ontology, and significant pathways affected by the targeted 
microRNAs. The researchers also aligned gene sequences between species, especially in the case 
of CHO cells where knowledge of genome is less evolved than that of the human genome [33, 53, 
57]. These bioinformatics tools, also summarized in Table 1-2, help provide a comprehensive 
analysis ensuring a robust approach to improving recombinant protein production. 
1.5 Additional non-coding RNA 
Additional non-coding RNAs that were used to improve recombinant protein production include 
short hairpin RNA (shRNA), small interfering RNA (siRNA), mitochondrial genome-encoded 
small RNA (mitosiRNA), and sineUP. Other non-coding RNA molecules, such as PIWI-
interacting RNA, and circular RNA, also have the potential to be used as targets for cellular 
engineering, but have yet to be tested [63]. 
1.5.1 short hairpin RNA 
Short hairpin RNAs (shRNA) are DNA vector-based RNA interference that are produced as 
single stranded molecules, 50-70 nucleotide stem-loop structures, and are cleaved by the nuclease 
Dicer to enter the RNA-induced silencing complex in the same way as siRNA, which triggers an 
RNAi response [64]. A study using an shRNA targeting dihydrofolate reductase (dhfr) showed 
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improved productivity in CHO cells [65]. Based on available information about the commonly 
used dhfr and Methotrexate (MTX) gene amplification system, Hong et al. designed an RNA 
silencing vector to target dhfr in dhfr deficient and wild type CHO cells with eGFP, to create a 
high producing cell line with improved stability without MTX. Wu et al. [66] followed up with 
enhancing IgG expression in CHO cells by targeting dhfr using the same RNA silencing vector.  
1.5.2 small interfering RNA 
Small interfering RNAs are double stranded 21-25 base pair RNAs that operate similarly to 
microRNAs regulating gene expression by degrading mRNA after transcription [67]. The major 
difference between siRNA and microRNA is that siRNA binds perfectly to a single gene, while 
microRNA imperfectly targets multiple genes [68]. Several studies were conducted using 
exogenous siRNA to target specific genes for improving protein expression [63, 69-72]. These 
studies were primarily concentrated on targeting genes that are known to be involved with protein 
production for example, genes that reduce apoptosis. Recently, a genome-wide siRNA screen was 
performed by Xiao et al. [73] in an analogous manner to the microRNA screens above. Transient 
transfections of siRNA for identifying gene targets that can affect protein expression were 
conducted in HEK 293 cells. By using large-scale high-throughput format, three siRNA for each 
gene were transfected into luciferase expressing HEK 293 cells and their effect on luciferase 
production and cell viability was measured. The top 10 genes were confirmed with additional 
three siRNAs. From this study, OAZ1 was selected as a target gene for follow-up studies due to 
improvement expression of the luciferase protein in HEK293 cells [73].  
1.5.3 Mitochondrial genome-encoded small RNA 
Mitochondrial genome-encoded small RNAs (mitosRNA) are a class of small RNAs that are 
derived in the mitochondria from ‘housekeeping’ non-coding RNAs and function similarly to 
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microRNA [74]. In 2016 Pieper et al. [75] identified mitosRNA-1972 as a tool for improving the 
expression of IgG in CHO cells based on a BLAST alignment and knowledge about the function 
of the sequence. Once this was shown as a successful tool, they identified targets of the 
mitosRNA using next generation sequencing after transfecting with mitosRNA-1972, comparing 
gene expression at multiple time points. ShRNA expression plasmid transfections were then used 
as follow-up studies to confirm Cers2 and Tbc1D20 as targets of mitosRNA-1978. These two 
genes were then used to co-engineer CHO-IgG producer cells with a combined knockdown with 
shRNA [75]. 
1.5.4 SINEUP RNA levels  
SINEUPs are a new class of natural and synthetic antisense long non-coding RNAs that require 
an invSINEB2 element whose effect is to upregulate translation of partially overlapping sense 
coding mRNAs with no consequence to RNA levels [76, 77]. Patrucco et al. [78] manipulated 
these SINEUPs in CHO cells to improve secreted protein translation levels. SINEUPs that 
targeting cytosolic and secreted luciferase were also used to test the concept of SINEUPs and 
their ability to improve production. They then used SINEUPs to target therapeutic proteins, 
secreted ScFv, and a cytokine, successfully enhancing protein expression. 
1.6 Summary and Conclusions 
Small non-coding RNA particularly microRNA participate in many regulatory functions 
including cell cycle regulation and proliferation. By implementing this information, it is possible 
to target specific, well-known pathways, to achieve improved performance of the cells. However, 
the available information on microRNA effect is limited and different approaches are needed to 
achieve improved cell function by using microRNAs. One of the approaches described in this 
chapter is through identification of promising microRNA by utilizing microarrays. 
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Microarrays offer the ability to discover differentially regulated microRNAs based on conditions 
that are known to improve protein expression. Since the probes correspond to certain microRNAs 
or genes, the data analysis for microarrays, compared with other technologies such as Next 
Generation Sequencing, is relatively straight-forward, however, microRNA microarrays are 
limited to currently available microRNA probes. Cross-species microarrays have been used in 
place of CHO specific microarrays. 
MicroRNA library screenings use cells treated with multiple microRNAs in small-scale high-
throughput, format. To prepare for the screen, there is a need to optimize the transfections process 
and to choose an expressed protein that is possible to screen in this format such as a fluorescent 
marker. The microRNA library is growing with technology improvements, and the number of 
entries in miRbase database grew from 15,000 to almost 30,000 between 2010 and 2014 [79], and 
with it the size of the screen. The data analysis of a microRNA screening is a bit more involved 
than for that of the microarray since there are cell counts, protein amounts and specific protein 
production to consider for each microRNA.  
Next generation sequencing can be used in a similar manner as a microarray but does not require 
specific microRNA probes. It is therefore easier to use for species that do not have fully 
developed tools such as CHO. RNA from a good producing condition is compared to that of the 
wild type and up or down regulated microRNAs are identified. Instead of probes attached to a 
chip, the RNA is transcribed to labelled cDNA libraries and then fully sequenced. This produces 
a significant amount of data that can be analyzed using multiple methods, each attaining slightly 
different results. Several review articles describe the differences between microarrays and next 
generation sequencing [80, 81].  
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After identifying the microRNA target(s), from any of these screening technologies, validation is 
required. In the next step an improved producer stable cell line is created by over-expressing, or 
depleting the identified microRNA, in some cases using multiple microRNAs together for a 
synergistic effect. The gene targets of the microRNAs are often elucidated to determine more 
about the mechanism. Sometimes, after investigating the mechanism, a gene knockdown or over 
expression is performed to further improve recombinant production. From the small non-coding 
RNA studies, numerous microRNAs were identified as potential targets for engineering high 
expressing cells.  
An advantage of utilizing microRNA is the fact that a single construct targets multiple genes at 
the same time. However, this could also be a disadvantage since these targets are not fully 
elucidated. Some small ncRNA such as shRNA and siRNA are gene specific, narrowing the focus 
to one target gene and removing the uncertainty of undesired targets. As more information 
becomes available concerning small non-coding RNA molecules, more applications become 
possible for improving protein production, such as the use of mitosRNA and SINEUP. However, 
these agents are new and the technology has not yet evolved to give good screening tools to 
provide a quick way to improve protein expression, but likely will be available in the future.  
In summary: Using non-coding RNA as a method of modifying cell properties is an efficient 
alternative to classical cloning methods for improving recombinant protein expression since non-
coding RNA does not require protein translation. Several methods are currently being applied for 
identifying and utilizing non-coding RNAs for improved recombinant protein expression from 
mammalian cells. By using approaches that consider known growth or production processes and 
working backwards to identify the non-coding RNA related to that specific processes, or by 
conducting broad screening of microRNAs or siRNAs, specific targets have been identified. 
Because of this work, significant improvement in production level of several recombinant 
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proteins have been achieved by affecting apoptosis, cell proliferation, and cell cycle distribution. 
Rapidly advancing technology continues to provide more methods for identifying and using 
different non-coding RNAs. Since advancement in technology brings a significant amount of 
data, there is a need for robust bioinformatics tools. As more information about non-coding RNAs 
and their mechanisms becomes available, their usefulness for improving recombinant protein 
expression from mammalian cells will continue to increase. In chapter two, target genes are 
identified for a microRNA that improves protein expression in HEK cells. 
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Figures and Tables 
Figure 1-1: Example workflow for high-throughput microRNA library screen
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Table 1-1: Summary of microRNA screening methodologies 
Year Initial Screen Researchers Type of Cells Conditions evaluated in initial screen Reference 
Previously identified microRNAs 
2015 mir mimics and mir-34 sponge decoy Kelly et al. CHO apoptosis and cell growth [29] 
2015 mir mimics and mir-23 sponge decoy Kelly et al. CHO energy metabolism [30] 
Microarray 
2007 human, mouse and rat microRNA arrays 
Gammell et 
al. CHO temperature shift [28] 
2009 human and mouse microRNA arrays Koh et al. HEK293 3 stages of batch culture [35] 
2011 human microRNA arrays Barron et al. CHO temperature shift [32] 
2011 mouse and rat microRNA arrays Druz et al. CHO apoptosis [36] 
2011 human, mouse and rat microRNA arrays Lin et al. CHO 
producing lines compared to 
parental and MTX 
amplification 
[39] 
2014 cross-species microRNA and mRNA arrays 
Maccani et 
al. CHO 
high producing cell lines 




human for HELA, mouse, rat, 
and human for CHO 
microRNA arrays 
Emmerling 
et al. HELA and CHO mild hypothermia [41] 
2016 human, mouse, rat, viral microRNAs Klanert et al. CHO 
growth rate in multiple cell 
lines [42] 
microRNA screen 
2013 human microRNA library Strotbek et al. CHO IgG [49] 
2014 murine microRNA library Fischer et al. CHO SEAP [44] 
2015 human microRNA library Xiao et al. HEK293 neurotensin receptor [43] 
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2017 human microRNA library Meyer et al. HEK293 antibody [51] 
Next Generation Sequencing 
2011 small RNA transcriptome Hackl et al. CHO identified conserved and novel CHO microRNAs [53] 
2012 microRNA Jadhav et al. CHO effects of overexpressing microRNA [54] 
2014 microRNA Loh et al. CHO looking at profile of different expression level cultures [56] 
2016 microRNA and mRNA Pfizenmaier et al. CHO osmotic shift [58] 
2016 microRNA Stiefel et al. CHO 
biphasic fed batch cultivation 
of high low and non-






Table 1-2: Summary of bioinformatics programs 
microRNA target prediction  
miRwalk Collection of experimentally validated and 
predicted microRNA binding sites from 
multiple resources  
http://mirwalk.uni-hd.de/  [82] 
miRbase Collection that provides a registry of 




Algorithm that predicts microRNA targets 
based on sequence complementarity, energy 
binding and evolutionary conservation  
http://www.microrna.org/  [84] 
PITA Database based on algorithms predicting 




RNAhybrid Database based on algorithms predicting 





DIANA tools Database based on algorithms predicting 





targetScan Database based on algorithms predicting 
targets based on site recognition  
http://www.targetscan.org/vert_71/ [88] 
EiMMo Database based on algorithms predicting 




miRtarbase Database based on experimentally validated 
microRNA/mRNA interactions 
http://mirtarbase.mbc.nctu.edu.tw/ [62] 
Mirdb Database for microRNA target prediction and 
functional annotation  
http://mirdb.org/  [79] 
DAVID Database for identifying gene ontology but 
can and has also been used for identifying 
microRNA targets 
https://david.ncifcrf.gov/  [90] 
    
Biological Processes, Gene Ontology, and Protein Identification 
PANTHER Database for gene ontology and gene 
clustering analysis and gene products 
http://pantherdb.org/ [91] 
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MASCOT Software program for identifying proteins http://www.matrixscience.com/ 
 
HomoloGene Database containing information about genes 
that have been used to study homology 
between species as well as for providing 




GeneCards Database containing information about genes 
that have been used to study homology 
between species as well as for providing 
information about gene function 
http://www.genecards.org/  
 
BLAST Basic local alignment search tool (i.e. Blast) 
utilizes the discontiguous megablast 
algorithm can be used to align gene 





edgeR “R” software program package for 





maSigPro “R” software program package for regression 
analysis and differential expression analysis 




LIMMA “R” software program package for linear 
models and differential expression analysis 










Gene ontology database primarily for mouse 
genes 
http://www.informatics.jax.org/  [96] 
Vmatch Sequence analysis software http://www.vmatch.de/  
 










*all accessed 14 November 2017  
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Chapter 2 Identifying HIPK1 as target of mir-22-3p enhancing 
recombinant protein production from HEK 293 cell by using 
microarray and HTP siRNA screen 
Abbreviations: CHO, Chinese hamster ovary; DEG, differentially expressed genes; EMILIN3, 
elastin microfibril interfacer 3; FRAT2, Frequently Rearranged In Advanced T-Cell Lymphomas 
2; GPC3, glypican3 hFc-fusion protein; HEK, human embryonic kidney; HIPK1, homeodomain 
interacting protein kinase 1; HTP, high throughput; LIN7C, lin-7 homolog C, crumbs cell 
polarity component; LUC2, firefly luciferase also called Photinus pyralis; MURC, muscle-
restricted coiled-coil protein; PRPF38A, pre-mRNA processing factor 38A; 
2.1 Summary 
In a previous study, by conducting a high-throughput screening of the human microRNA library, 
several microRNAs were identified as potential candidates for improving expression. From these, 
mir-22-3p was chosen for further study since it increased the expression of luciferase, two 
membrane proteins and a secreted fusion protein with minimal effect on the cells’ growth and 
viability. Since each microRNA can interact with several gene targets, it is of interest to identify 
the repressed genes for understanding and exploring the improved expression mechanism for 
further implementation. In this chapter, a novel approach for identification of the target genes is 
described; integrating the differential gene expression analysis with information obtained from 
our previously-conducted high-throughput siRNA screening. The identified genes were validated 
as being involved in improving luciferase expression by using siRNA and qRT-PCR. Repressing 
the target gene, HIPK1, was found to increase luciferase and GPC3 expression 3.3-fold and 2.2-
fold respectively.  
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2.2 Introduction 
As previously mentioned, enhancing recombinant protein expression from mammalian cells is of 
interest to the pharmaceutical, biotechnology, and academic fields for the purpose of obtaining 
proteins needed for therapeutic, biochemical, and structural studies [97]. Current approaches for 
improving protein production are based on modifying growth strategies, optimizing media 
composition, genetically altering the producing cells [98], and by improving the downstream 
processing [99]. Chapter one discussed the use of small non-protein-coding RNA, microRNA and 
siRNA, that has recently been shown to be a promising methodology for improving protein 
expression by identifying specific genes and by altering gene expression [23, 73, 100, 101].  
MicroRNAs, are natural cell products, approximately 22 nucleotides in length that, in their native 
form, modify gene-expression post-transcriptionally by competitive binding to mRNA, repressing 
translation or causing mRNA destabilization [102]. The microRNA active site is approximately 
seven base pairs at the 5’ end of the molecule known as the “seed” which can target multiple 
genes. Single microRNA can, therefore, affect the expression of more than one gene and several 
algorithms are available to predict these genes [103]. The change in expression of multiple direct 
and indirect gene targets, can have a synergistic effect whereby small changes of multiple genes 
can have a significant effect on different pathways including recombinant protein production 
[100].  
Expression of various recombinant proteins including secreted proteins, membrane proteins, 
antibodies, and viral vectors, has been found to be improved following the addition or deletion of 
microRNAs. The search for the specific affected genes was done by using microarrays, high-
throughput screening, next generation sequencing, and/or quantitative reverse transcription 
Polymerase Chain Reaction (qRT-PCR) [23, 26, 101]. While these studies did not describe the 
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specific mechanism by which the microRNA acted, they identified genes and pathways involved 
in apoptosis, HDAC5 modulation, and the ubiquitin pathway [29, 34, 45, 47].  
Most studies associated with microRNA effect on protein production have been done in Chinese 
hamster ovary cells (CHO) which are the chosen producers for monoclonal antibodies that are 
being used for therapeutic purposes [23]. This work was concentrated on human embryonic 
kidney (HEK) cells that can perform post-translational modification and therefore are reasonable 
alternatives for expression of specific proteins such as human coagulation factors, growth factors 
and hormones [7, 104]. Also, compared with the CHO genome, the human genome is more 
widely understood and therefore more tools such as microarrays, microRNA mimics and siRNAs 
have been created.  
Using a previously conducted high-throughput human microRNA screen in HEK 293 cells, mir-
22-3p was identified as a promising candidate for improving expression of luciferase (Luc) 
reporter, two hard-to-express membrane proteins, Neurotensin Receptor (NTSR1) and Serotonin 
transporter (SERT), as well as secreted glypican-3 hFc-fusion protein (GPC3-hFc) [43]. In this 
chapter, genes affected by this specific microRNA are identified through the implementation of 
differential gene expression analysis together with data obtained from our previously conducted 
genome scale siRNA study [73]. The results of this combined approach can provide a better 
understanding of the mechanism by which this specific microRNA improved recombinant protein 
expression. Repressing the target gene, HIPK1, was found to increase luciferase and GPC3 




2.3 Materials and Methods 
2.3.1 Cell lines and cultures 
A CMV-LUC2-Hygro HEK293 cell line constitutively expressing firefly luciferase was 
purchased from Promega (Madison, WI). An HEK 293 cell line constitutively expressing 
glypican-3 hFc-fusion protein (GPC3-hFc) was a gift from Dr. Mitchell Ho (National Cancer 
Institute, National Institutes of Health, Bethesda, MD). Experiments were completed with cells 
between passage numbers 6 and 30. Cells were maintained in 10% Fetal Bovine Serum (Atlanta 
Biologicals, Flowery Branch, GA) in Dulbecco's Modified Eagle Medium (DMEM, Gibco, 
Gaithersburg, MD) with penicillin/streptomycin (Gibco) in a humidified incubator set at 5% CO2 
and 37°C.  
2.3.2 Transient miRNA and siRNA transfection  
Transfections were performed in 24-well plates with miScript miRNA mimics (Qiagen, Hilden 
Germany) or SilencerSelect siRNA (Life Technologies, Waltham, MA), a SilencerSelect 
Negative Control #2 or a lethal AllStars death control siRNA (Qiagen). Three different cultures 
(biological triplicates) of cells were transfected in duplicates. In each well, 250 μL of serum-free 
DMEM containing 3.25 μL Lipofectamine RNAiMax (Life Technologies) was added to 20 pmol 
of miRNA or siRNA. After incubation at room temperature for 15 min, 75,000 cells in 250 μL of 





2.3.3 Luciferase activity, western blot, and cell viability assays 
Luciferase expressing cells were transfected as above. Seventy-two hours after transfection, cells 
were transferred to 96-well plate for luciferase and cell viability assays. The remainder of the 
cells were concentrated into a pellet for RNA extraction. The cells in the 96-well plate were 
measured for luciferase with ONE-Glo™ Reagent (Promega) and for viability with CellTiter-
Glo™ Reagent (Promega), using a SpectraMax i3 plate reader (Molecular Devices, San Jose, CA) 
according to the manufacturer’s protocol. Luciferase per cell was calculated by dividing the 
relative light units of the luciferase assay by the relative light units of the cell viability assay. 
Percentages were calculated dividing the result by that of the negative control and multiplying by 
100. P-values were calculated with a two-sample unpaired t-Test assuming unequal variances 
with the Data analysis package in Excel. 
For the western blot, luciferase expressing cells were transfected as above in duplicates. Seventy-
two hours after transfection cells were washed with cold PBS and lysed using RIPA buffer with 
protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific, Waltham, MA). Lysates 
from the duplicate wells were combined and diluted with PBS to equal concentrations. Proteins 
were separated with a NuPAGE 4-12% bis-tris gel (Thermo Fisher Scientific) at 200 V for 50 min 
and transferred to a nitrocellulose membrane using the iBlot Gel Transfer System (Invitrogen, 
Carlsbad, CA) using P8 for 8 min. This was then used for immunodetection with mouse anti 
luciferase at a 1:1,500 dilution (Thermo Fisher Scientific) and mouse anti-β-actin at a 1:1,000 
(Sigma-Aldrich, St. Louis, MO) as primary antibodies and an HRP conjugated goat anti-mouse 
secondary antibody at a 1:5,000 (KPL, Milford, MA). Signals were detected with an ECL PLus 
chemiluminescence reagent (Thermo Fisher Scientific). The membrane was stripped between 
primary antibodies using Restore™ plus western blot stripping buffer (Thermo Fisher Scientific). 
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2.3.4 GPC3-hFc cell viability and ELISA assays 
GPC3-hFc expressing cells were transfected as above. Seven days after transfection, the 
supernatant was collected and centrifuged for ELISA assay to measure the GPC3-hFc 
concentration. Cell counts and viability were determined using a CEDEX HiRes cell 
quantification system (Roche, Indianapolis, IN). The remaining cells were concentrated for RNA 
extraction.  
A 96-well MaxiSorp high binding plate (Nunc, Roskilde, Denmark) was coated with 5 μL/mL 
AffiniPure F(ab’)2 Fragment Goat-anti-human IgG (Jackson ImmunoResearch Laboratories, 
West Grove, PA) in PBS 50 μL per well. After overnight incubation at 4°C, the plate was washed 
with PBS containing 0.05% Tween 20 (PBST) and blocked with 3% milk in PBS for 30 min at 
37°C. Prediluted expression medium, starting at 40-fold and using 1:2 serial dilutions, was added 
at 50 μL per well and incubated at 37°C for 30 min. After washing twice with PBST, 50 μL per 
well of 1:4000 dilution of Peroxidase conjugated AffiniPure Goat-anti-human IgG (Jackson 
ImmunoResearch Laboratories) in blocking buffer were added and the plate was incubated at 
37°C for 30 min. The plate was washed 4 times with PBST, and TMB Microwell Peroxidase 
Substrate System (KPL) was used to detect quenching with 1 M phosphoric acid, after incubation 
for 5 min at room temperature. Absorbance was read with a SpectraMax i3 plate reader 
(Molecular Devices) at 450 nm. The amount of GPC3-hFc was determined by GPC3-hFc per cell 
production was quantified by comparing to a standard. The GPC3-hFc per cell production was 
determined by dividing GPC3-hFc by the viable cell number. Percentages were calculated 
dividing the result by that of the negative control and multiplying by 100. P-values were 
calculated with a two-sample unpaired t-Test assuming unequal variances with the Data analysis 
package in Excel. 
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2.3.5 RNA extraction 
Total RNA, including microRNA, was extracted from the cell pellets of transfected cells with the 
miRNEasy kit with DNase Digestion (Qiagen), following the manufacturer’s protocol, with an 
extra RPE buffer (Qiagen) wash. The extraction process involved lysing the cells and purifying 
with a spin column. RNA concentration and quality were determined with the NanoDrop 2000 
Spectrophotometer (Thermo Fisher Scientific) and Agilent 2100 Bioanalyzer (Agilent, Santa 
Clara, CA).  
2.3.6 Microarray 
Triplicates of luciferase-expressing cells transfected with either mir-22-3p or negative control 
were used to extract RNA for microarray analysis. The GeneChip Human Gene 2.0 ST array and 
the GeneChip WT Plus reagent kit (Affymetrix, Santa Clara, CA) were used to measure protein 
coding and long intergenic non-coding RNA transcripts. The Biopolymer/Genomics Core Facility 
at the University of Maryland (Baltimore, MD) performed the reverse transcription, 
hybridization, and data collection for the microarray. For gene identification, the raw cell files 
from the microarrays were analyzed by using both Gene ANOVA and alt-splice gene ANOVA 
workflow of the commercial software Partek Genomic Suite (http://www.partek.com/pgs). Genes 
with an absolute value fold change of at least 1.5 (Supplemental Table S 2-1) were used.  
2.3.7 nCounter XT CodeSet Gene Expression Assay 
The RNA extracted from the miRNA-transfected luciferase-expressing cells was used to confirm 
gene expression with the nCounter analysis. A custom CodeSet (NanoString Technologies, 
Seattle, WA) was created for the 27 genes identified by the microarray. The RNA was hybridized 
with the CodeSet and ProbeSet following the manufacturer’s protocol using 100 ng RNA. The 
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data collection was performed by the CCR Genomics Core at the National Institutes of Health, 
with the automated processing nCounter instrument (NanoString Technologies). The raw data 
files were analyzed using nSolver (NanoString Technologies). Genes were considered if they had 
a p-value less than 0.05.  
2.3.8 qRT PCR 
For microRNA expression analysis, miScript PCR starter kit (Qiagen) was used with the mir-22-
3p miScript Primer Assay (Qiagen) following the manufacturer’s instructions. Briefly, 100 ng 
RNA was transcribed to cDNA by incubating with the Reverse Transcriptase mixed with high 
flex buffer. Then the qPCR was performed using the SYBR green mix, primer assay and 
universal primer with the prescribed conditions and measured on the 7500 Fast Real Time PCR 
System (Applied Biosystems, Foster City, CA). Relative gene expression was calculated using 
the 2-∆∆CT method with human RNU6B as the reference gene.  
For gene expression analysis, RNA extracted from transfected cells was transcribed to cDNA 
using reverse transcriptase (Life Technologies) following the manufacturer's protocol: 100 ng of 
RNA were mixed with reverse transcriptase master mix and incubated at 37°C for 60 min 
followed by 95°C incubation for 5 minutes. Primers against the genes, homeodomain interacting 
protein kinase 1(HIPK1), frequently rearranged in advanced t-cell lymphoma 2 (FRAT2), 
Photinus pyralis (LUC2) were added in triplicate to SYBR green PCR master mix with 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) for normalization along with the 
respective RNA. The quantitative PCR amplifications were measured on the 7500 Fast Real Time 
PCR System (Applied Biosystems) with initial 10 min at 95°C followed by 40 cycles of 15 
seconds at 95°C and 10 seconds at 65°C. Relative gene expression was calculated using the 2-∆∆CT 
method with GAPDH as the reference gene.  
31 
2.4 Results 
2.4.1 Work Flow 
The work flow of the gene identification process is shown in Figure 2-1. Following transfection 
of the HEK cells with hsa-mir-22-3p, microarray analysis was performed and 208 down-regulated 
genes were identified. These down-regulated genes were compared with the list of the predicted 
targets [79] and 27 genes were selected and confirmed. Then, from the previously conducted 
genome-wide siRNA screening [73], 1,856 genes that showed above 60% improvement of 
luciferase expression (when inhibited by siRNA) were compared with the down-regulated genes 
obtained from the microarrays. Six genes were found to be included in both groups and were 
selected for follow-up siRNA studies.  
2.4.2 Effect of hsa-mir-22-3p on protein expression  
The effect of hsa-mir-22-3p on the expression of luciferase from HEK 293 cells was verified by 
transfecting the cells with the mir-22-3p. The luciferase expression, cell viability and western blot 
results are shown in Figure 2-2. The overall luciferase expression in the transfected cells was 3.7 
times higher than the expression in cells treated with negative control. The western blot also 
shows increased luciferase protein in cells treated with mir-22 compared to the negative control. 
Following the transfection, the amount of mir-22-3p in the cells was measured using qPCR and 
was found to be 1038 ± 235-fold higher than the amount in the controlled cells.  
2.4.3 Identification potential targets of mir-22-3p that involved in improved protein expression.  
A HuGene 2.0 microarray analysis, comparing RNA from HEK 293 luciferase-expressing cells 
transfected with mir-22-3p with RNA from cells transfected with negative control, was 
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performed. The data have been deposited in NCBI's Gene Expression Omnibus [105] and are 
accessible through GEO Series accession number GSE92599. A one-way ANOVA analysis of the 
microarray data of the 34,460 unique genes, identified 405 significantly differentially expressed 
(DEG) gene with p-value of less than 0.05 and a fold change greater than 1.5 or less than -1.5 
(Supplemental Table S 2-1). 
Since miRNA typically regulate mRNA by repression, the 405-gene list was narrowed down to 
218 significantly down-regulated genes with fold change of less than -1.5. To identify targets of 
mir-22-3p that are potentially involved in the increased luciferase expression, the 218 
significantly down-regulated genes, were compared with the 430 predicted targets for mir-22-3p 
included in the miRDB database predictions by the MirTarget bioinformatics tool [79]. This 
comparison identified 27 genes that were included in both the down-regulated microarray list and 
the miRDB database; the genes are summarized in Table 2-1. To confirm the down-regulation of 
the 27 identified genes from the microarray, an nCounter analysis was performed. This analysis 
verified that 26 of the genes were down-regulated with p-value less than 0.05 in luciferase 
expressing cells treated with mir-22-3p, compared with cells treated with a negative control 
(Table 2-1).  
For further identification of the directly-involved genes the 27 down-regulated genes, that were 
also predicted targets of mir-22-3p, were compared with a subset of genes from a previously 
performed high-throughput siRNA screen that measured the effects of 64,755 individual siRNAs 
(representing 21,585 genes) on luciferase expression [73]. Since the mir-22-3p increased the 
luciferase expression, the 27 previously identified genes were compared to the siRNAs that 
improved luciferase expression by at least 60% in relation to the negative control; which created a 
list of only 1,856 genes from the siRNA high-throughput screen. Six of the 27 previously 
identified genes HIPK1, FRAT2, elastin microfibril interface-located protein 1 (EMILIN3), lin-7 
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homolog C crumbs cell polarity complex component (LIN7C), muscle-restricted coiled-coil 
protein (MURC), and pre-mRNA processing factor 38A (PRPF38A) were also found on this short 
list of siRNAs. These genes were selected for follow up studies.  
2.4.4 Validation of mir-22-3p identified targets 
To validate the mir-22-3p selected targets, HEK cells expressing luciferase and HEK cells 
expressing GPC3-hFc were transfected with siRNA against each of the six identified genes 
(Supplemental Table S 2-2); the effect of their inhibition on both expression and viability is seen 
in Figure 2-3. Decreasing HIPK1 expression increased luciferase activity by 3.2-fold and GPC3 
expression 2.3-fold, while decreasing FRAT2 expression increased luciferase activity 3-fold with 
no effect on GPC3 expression. Decreasing expression of LIN7C and MURC increased modestly 
both luciferase and GPC3 expression, while decreasing expression of PRPF38A although 
modestly increased luciferase and GPC3 expression has negative effect on cell viability. 
Co-repression effect of HIPK1, FRAT2 and LIN7C, the top three siRNAs that were identified 
improving luciferase and co-repression effect of HIPK1, MURC and LIN7C the three-top siRNA 
that were identified improving GPC3 expression is shown in Figure 2-4. Co-repression of the 
luciferase expressing cells using siRNA against both HIPK1 and FRAT2 had a synergistic effect, 
increasing specific luciferase expression 4.4-fold, which is a larger improvement compared with 
siRNA inhibiting HIPK1 only (Figure 2-4A and B). Co-repressing HIPK1 with MURC or LIN7C 
in GPC3 cells increased the cell viability 1.9-fold and 2-fold respectively and the cell specific 
productivity 1.8-fold and 1.6-fold respectively which does not display a synergistic improvement 
(Figure 2-4C). However, co-repressing MURC and LIN7C together in cells expressing GPC3 led 
to productivity increase of 2.5-fold compared with negative control which is improved compared 
to inhibiting MURC individually. 
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Additional confirmation that the increased recombinant proteins expression was associated with 
the decreased HIPK1 transcription was obtained by quantitative reverse transcription polymerase 
chain reaction (RT-qPCR) analysis (Table 2-2). Cells treated with siRNA against HIPK1 showed 
64% reduced transcription, and at the same time the luciferase gene transcription increased by 
200%. An additional validation was done by using an nCounter analysis that confirmed that, 
when treated with the respective siRNA, the expression of HIPK1 was decreased and luciferase 
was increased. (Supplemental Table S 2-3).  
2.4.5 Off-target effects analysis  
Off-target effects are frequent sources for false positives in RNAi screening [106]. To minimize 
the possibility that observed luciferase activity was due to seed-based off-target effects, each 
siRNAs effect was compared to all other siRNAs from the screen having the same seed sequence 
(bases 2-7 or 2-8 of the guide strand of the seed sequence) [107]. By plotting the luciferase 
activity for the siRNAs designed against a given gene (three different siRNAs for each gene in 
the primary screen) along with the results for other siRNAs with the same seed sequence, an 
assessment was made as to whether the observed results were attributable to knockdown of the 
gene itself or were the result of seed-based off-target effects. From this analysis, Life 
Technology’s Silencer Select siRNAs ID s47549 for HIPK1 (Supplemental Table S 2-2) was 
confirmed as the most representative for true results. 
2.5 Discussion 
This work shows the benefit of using microarray analysis together with high throughput siRNA 
screen to investigate the effect of mir-22-3p on recombinant protein production from HEK cells. 
By using this approach is was possible to identify a possible target out of the 430 predicted 
targets genes that, when downregulated, enhanced productivity in two protein expressing cell 
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lines. The findings demonstrated that HIPK1 is a predicted target gene of mir-22-3p 
(Supplemental Figure S 2-1); which is associated with increased recombinant luciferase 
expression, an intracellular protein and GPC3, a secreted protein. When cells were transfected 
with mir-22-3p mimic, HIPK1 was down-regulated while luciferase expression increased, and 
was confirmed by transfecting the cells with siRNA against HIPK1. Suppressing HIPK1 with 
siRNA was also effective at increasing both the overall and per-cell expression of the secreted 
glypican-3 hFc-fusion protein, GPC3-hFc.  
Recent studies demonstrate that mir-22 has different roles in different conditions. In the case of 
human glioblastoma [108], mir-22 inhibited proliferation [109] while in traumatic brain injury it 
prevented apoptosis [110]. The mature mir-22-3p is normally studied as part of general profiling 
of microRNA related to diabetes, hypertension atopic dermatitis and colorectal cancer [111-114]. 
There are few studies where, transcription factor 7 (TCF7) and regulator of G-protein signaling 2 
(RGS2), gene targets of mir-22-3p were specifically differentiated from its counterpart mir-22-5p 
[115, 116]. Other targets of mir-22 are merely predicted with bioinformatics and have little 
experimental evidence to date [117]. Therefore, it is possible that by using the predicted target 
database, genes that are affected by mir-22-3p and improve protein expression will be identified 
but are not direct targets. Since microRNAs are known to target more than one gene at a time and 
can indirectly target multiple additional genes, one of the goals of this work was to identify genes 
affected by mir-22-3p that are specifically associated with the increased expression of 
recombinant protein. 
In a previous high-throughput screen [43], mir-22-3p was identified as a promising candidate for 
improving recombinant protein production, such as membrane proteins, a secreted fusion protein 
and an internal luciferase reporter. Since microRNAs target multiple genes, their overexpression 
can have unintended off-target negative effects. Identifying differentially regulated gene targets 
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of the microRNA may lead to a better understanding of how the microRNA affects recombinant 
protein expression, with the possibility of minimizing off-target effects [45]. In the current study 
microarray analysis was used to identify the differentially regulated genes when the cells were 
treated with mir-22-3p. This traditional approach is an efficient method for identifying 
differences in gene expression; it requires less intensive bioinformatics analysis than RNA 
sequencing [118] since the probes are associated with known genes. Individually observing the 
effect of the down-regulated genes by knocking them down with siRNA is another way to 
determine which genes are involved in increasing the recombinant protein production. By 
comparing the list obtained from the microarray analysis to the results of the high-throughput 
siRNA screen and to the predicted list of targets, together with performing common seed analysis 
and verifying with siRNA and nCounter gene expression analysis, the HIPK1 gene was selected. 
Using siRNA, the luciferase expression increased 3.3-fold when HIPK1 was inhibited and 4.4-
fold when co-inhibited with FRAT2.  
HIPK1 encodes the homeodomain interacting protein kinase 1, highly conserved member of the 
Serine/Threonine family of protein kinases [119]. The main function of HIPK1 is to 
phosphorylate the homeodomain transcription factors’ hydroxyl groups. This can have co-
repressive effects on genes involved in transcription of RNA polymerase II which is responsible 
for transcribing mRNA and the small RNA precursors [119-122]. In addition, HIPK1 modulates 
different stress pathways implicating them in several types of cancer [123]. HIPK1 has been 
linked to apoptosis pathways through p53 [124, 125] and apoptosis signal-research regulating 
kinase1 (ASK1) [126], to growth pathways through mediation of death-domain associated protein 
6 (Daxx) [127] and also has been found to be involved with the WNT/β-catenin signaling 
pathway regulating transcription, cell fate and cell proliferation [128].  
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Four of the six genes tested with siRNA improved expression of both luciferase and the secreted 
GPC3. In addition to HIPK1, these were LIN7C, MURC and PRPF38A. LIN7C is involved in 
activating calcium and potassium channels and combines with lin2 and the rest of lin7 to form the 
lin27 signaling complex [129]. MURC is a muscle-restricted coiled-coil protein that modulates 
the Rho/ROCK pathway and makes up caveolea in skeletal and cardiac muscles [130]. PRPF38A, 
pre-mRNA processing factor 38A, part of the human spliceosome, has a vital role in the cell and 
its repression with siRNA drastically decreases the cell viability [131]. While HIPK1, LIN7C, 
MURC and PRPF38A appear to improve both luciferase and GPC3expression, FRAT2 and 
EMILIN3 improved only luciferase expression. FRAT2 is Glycogen Synthase Kinase 3 (GSK3) 
binding protein that has a role in activating the WNT/β-catenin signaling pathway [132]. 
EMILIN3, elastin microfibril interfacer 3 is a member of the EMU gene family that interacts with 
extracellular matrix molecules and functions as an extracellular regulator of the transforming 
growth factor beta (TGF-β) ligands activity [133]. Repressing FRAT2 and EMILIN3 these two 
genes likely act in a more specific manner to increase luciferase expression thereby making them 
less useful for general protein expression. 
Since microRNA functions by repressing multiple genes simultaneously, co-inhibition of the top 
three genes for both luciferase and GPC3-hFC expressing cells was carried out to determine if 
suppressing two genes would have a synergistic effect on protein expression. This does appear to 
be the case since simultaneously inhibiting HIPK1 and FRAT2 increased luciferase expression. 
However, the combination of HIPK1 and LIN7C did not have an improved productivity over 
HIPK1 individually. The combination of MURC and LIN7C, two genes that only had minor 
improvements in productivity of GPC3 individually, had a large improvement when combined. 
Certainly, systematic high-throughput siRNA screen would be a more efficient way of 
determining which combination of genes complement each other for improving protein 
expression than drawing conclusions based on combinations of individual target genes.  
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2.5.1 Conclusion  
The data presented in this chapter, confirmed that HIPK1 is involved in the increased expression 
of recombinant luciferase and the secreted recombinant GPC3-hFc from HEK 293 cells following 
transfection with mir-22-3p. As a result of exposing the cells to mir-22-3p, several genes are 
being down regulated, but the overall process that leads to the increased expression is not fully 
understood. Comparing microarray analysis with siRNA screening and performing common seed 
analysis was an efficient way to narrow the list of potential genes and to focus on a few that, 
when suppressed, significantly increased the specific productivity of luciferase and GPC3. A 
study of HIPK1 effects on recombinant protein production using a stable HIPK1 knockout cell 
line is detailed in the next chapter, compared to the effects of stable overexpression of mir-22 on 
protein expression.  
Contributions from collaborators: 
Dr. Madhu Lal-Nag and Dr. Eugen Buehler assisted with experiment design and data analysis for 
the common seed analysis.  
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Figures and Tables  
Figure 2-1: Work flow of identifying genes  
Work flow of identifying genes affected by mir-22-3p that improve recombinant protein 







Figure 2-2: Effect of miRNA-22-3p on luciferase expression.  
(A) Overall luciferase yield, cell viability and luciferase per cell compared with negative control 
cells (Neg Control). (B) Western blot of luciferase expressing HEK cells treated with mir-22-3p 
compared to NC. Experiments were carried out with biological triplicates. Error bars represent 






Figure 2-3: Effect of the elected siRNA on luciferase and GPC expression.  
(A) Relative luciferase yield, cell viability and luciferase per cell of luciferase expressing HEK 
cells treated with the selected siRNAs compared with negative control cells. (B) Western blot of 
luciferase expressing HEK cells treated with the selected siRNAs. (C) Relative GPC3-hFc yield, 
cell viability and GPC3-hFc per cell of GPC3-hFc expressing HEK cells treated with the selected. 
Experiments were done with biological triplicates. Error bars represent Standard Error of the 
Mean (SEM). * indicates P ≤ 0.05, ** indicates P ≤ 0.01, and *** indicates P ≤ 0.001 relative to 




Figure 2-4: Effect of co-transfection of the selected siRNA on luciferase and GPC expression. 
(A) Relative luciferase yield, cell viability) and luciferase per cell of luciferase expressing HEK 
cells treated with 3 different siRNAs combinations (HIPK1 and FRAT2, HIPK1 and LIN7C, 
FRAT2 and LIN7C) compared with negative control cells. (B) Western blot of luciferase 
expressing HEK cells treated with the same siRNA combination as A. (C) Relative GPC3-hFc 
yield, cell viability and GPC3-hFc per cell of GPC3-hFc expressing HEK cells treated with 3 
different siRNAs combinations (HIPK1 and LIN7C, HIPK1 and MURC, LIN7C and MURC), 
compared with NC. Experiments were done with biological triplicates and error bars represent the 





Table 2-1: 27 predicted mir-22-3p targets from the microarray analysis  
Gene 
























-2.01 93 0.0079 -2.64 Y 
HOXA4 homeobox A4 -1.99 82 0.0003 -2.31 Y 
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Table 2-2: qRT-PCR of luciferase expressing cells treated with siRNA  
HIPK1 expression 
Sample Fold differencea Rangeb 
Luciferase Control 1 (0.81-1.24) 
siRNA against HIPK1 0.36 (0.30-0.43) 
siRNA against HIPK1 and 
FRAT2 0.34 (0.32-0.36) 
LUC2 expression 
Sample Fold differencea Rangeb 
Luciferase Control 1 (0.80-1.25) 
siRNA against HIPK1 3 (2.71-3.33) 
siRNA against HIPK1 and 
FRAT2 5.7 (5.40-6.01) 
 
 
aFold difference is siRNA relative to control calculated by 2- ΔΔCT with CT of siRNA and CT of 





Supplemental Figure S 2-1: hsa-mir-22-3p and target sequences.  
The sequence of hsa-mir-22-3p along with the sequence of the 3’UTR for HIPK1 and the 
predicted binding location for mir-22-3p in the 3’UTR. The predicted target is in blue bold and 
underlined.  





Predicted mir-22-3p target in HIPK1 3’UTR sequence [79]: 
    1 TTGGTGAGCA TGAGGGAGGA GGAATCATGG CTACCTTCTC CTGGCCCTGC 
GTTCTTAATA 
   61 TTGGGCTATG GAGAGATCCT CCTTTACCCT CTTGAAATTT CTTAGCCAGC 
AACTTGTTCT 
  121 GCAGGGGCCC ACTGAAGCAG AAGGTTTTTC TCTGGGGGAA CCTGTCTCAG 
TGTTGACTGC 
  181 ATTGTTGTAG TCTTCCCAAA GTTTGCCCTA TTTTTAAATT CATTATTTTT 
GTGACAGTAA 
  241 TTTTGGTACT TGGAAGAGTT CAGATGCCCA TCTTCTGCAG TTACCAAGGA 
AGAGAGATTG 
  301 TTCTGAAGTT ACCCTCTGAA AAATATTTTG TCTCTCTGAC TTGATTTCTA 
TAAATGCTTT 
  361 TAAAAACAAG TGAAGCCCCT CTTTATTTCA TTTTGTGTTA TTGTGATTGC 
TGGTCAGGAA 
  421 AAATGCTGAT AGAAGGAGTT GAAATCTGAT GACAAAAAAA GAAAAATTAC 
TTTTTGTTTG 
  481 TTTATAAACT CAGACTTGCC TATTTTATTT TAAAAGCGGC TTACACAATC 
TCCCTTTTGT 
  541 TTATTGGACA TTTAAACTTA CAGAGTTTCA GTTTTGTTTT AATGTCATAT 
TATACTTAAT 
  601 GGGCAATTGT TATTTTTGCA AAACTGGTTA CGTATTACTC TGTGTTACTA 
TTGAGATTCT 
  661 CTCAATTGCT CCTGTGTTTG TTATAAAGTA GTGTTTAAAA GGCAGCTCAC 
CATTTGCTGG 
  721 TAACTTAATG TGAGAGAATC CATATCTGCG TGAAAACACC AAGTATTCTT 
TTTAAATGAA 
  781 GCACCATGAA TTCTTTTTTA AATTATTTTT TAAAAGTCTT TCTCTCTCTG ATTCAGCTTA 
  841 AATTTTTTTA TCGAAAAAGC CATTAAGGTG GTTATTATTA CATGGTGGTG 
GTGGTTTTAT 
  901 TATATGCAAA ATCTCTGTCT ATTATGAGAT ACTGGCATTG ATGAGCTTTG 
CCTAAAGATT 
  961 AGTATGAATT TTCAGTAATA CACCTCTGTT TTGCTCATCT CTCCCTTCTG TTTTATGTGA 
 1021 TTTGTTTGGG GAGAAAGCTA AAAAAACCTG AAACCAGATA AGAACATTTC 
TTGTGTATAG 
 1081 CTTTTATACT TCAAAGTAGC TTCCTTTGTA TGCCAGCAGC AAATTGAATG 
CTCTCTTATT 
 1141 AAGACTTATA TAATAAGTGC ATGTAGGAAT TGCAAAAAAT ATTTTAAAAA 
TTTATTACTG 
 1201 AATTTAAAAA TATTTTAGAA GTTTTGTAAT GGTGGTGTTT TAATATTTTA 
CATAATTAAA 
 1261 TATGTACATA TTGATTAGAA AAATATAACA AGCAATTTTT CCTGCTAACC 
CAAAATGTTA 
 1321 TTTGTAATCA AATGTGTAGT GATTACACTT GAATTGTGTA CTTAGTGTGT 
ATGTGATCCT 
 1381 CCAGTGTTAT CCCGGAGATG GATTGATGTC TCCATTGTAT TTAAACCAAA 
ATGAACTGAT 
 1441 ACTTGTTGGA ATGTATGTGA ACTAATTGCA ATTATATTAG AGCATATTAC 
TGTAGTGCTG 
 1501 AATGAGCAGG GGCATTGCCT GCAAGGAGAG GAGACCCTTG GAATTGTTTT 
GCACAGGTGT 
 1561 GTCTGGTGAG GAGTTTTTCA GTGTGTGTCT CTTCCTTCCC TTTCTTCCTC CTTCCCTTAT 
 1621 TGTAGTGCCT TATATGATAA TGTAGTGGTT AATAGAGTTT ACAGTGAGCT 
TGCCTTAGGA 
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 1681 TGGACCAGCA AGCCCCCGTG GACCCTAAGT TGTTCACCGG GATTTATCAG 
AACAGGATTA 
 1741 GTAGCTGTAT TGTGTAATGC ATTGTTCTCA GTTTCCCTGC CAACATTGAA 
AAATAAAAAC 
 1801 AGCAGCTTTT CTCCTTTACC ACCACCTCTA CCCCTTTCCA TTTTGGATTC 
TCGGCTGAGT 
 1861 TCTCACAGAA GCATTTTCCC CATGTGGCTC TCTCACTGTG CGTTGCTACC 
TTGCTTCTGT 
 1921 GAGAATTCAG GAAGCAGGTG AGAGGAGTCA AGCCAATATT AAATATGCAT 
TCTTTTAAAG 
 1981 TATGTGCAAT CACTTTTAGA ATGAATTTTT TTTTCCTTTT CCCATGTGGC 
AGTCCTTCCT 
 2041 GCACATAGTT GACATTCCTA GTAAAATATT TGCTTGTTGA AAAAAACATG 
TTAACAGATG 
 2101 TGTTTATACC AAAGAGCCTG TTGTATTGCT TACCATGTCC CCATACTATG 
AGGAGAAGTT 
 2161 TTGTGGTGCC GCTGGTGACA AGGAACTCAC AGAAAGGTTT CTTAGCTGGT 
GAAGAATATA 
 2221 GAGAAGGAAC CAAAGCCTGT TGAGTCATTG AGGCTTTTGA GGTTTCTTTT 
TTAACAGCTT 
 2281 GTATAGTCTT GGGGCCCTTC AAGCTGTGAA ATTGTCCTTG TACTCTCAGC 
TCCTGCATGG 
 2341 ATCTGGGTCA AGTAGAAGGT ACTGGGGATG GGGACATTCC TGCCCATAAA 
GGATTTGGGG 
 2401 AAAGAAGATT AATCCTAAAA TACAGGTGTG TTCCATCTGA ATTGAAAATG 
ATATATTTGA 
 2461 GATATAATTT TAGGACTGGT TCTGTGTAGA TAGAGATGGT GTCAAGGAGG 
TGCAGGATGG 
 2521 AGATGGGAGA TTTCATGGAG CCTGGTCAGC CAGCTCTGTA CCAGGTTGAA 
CACCGAGGAG 
 2581 CTGTCAAAGT ATTTGGAGTT TCTTCATTGT AAGGAGTAAG GGCTTCCAAG 
ATGGGGCAGG 
 2641 TAGTCCGTAC AGCCTACCAG GAACATGTTG TGTTTTCTTT ATTTTTTAAA 
ATCATTATAT 
 2701 TGAGTTGTGT TTTCAGCACT ATATTGGTCA AGATAGCCAA GCAGTTTGTA 
TAATTTCTGT 
 2761 CACTAGTGTC ATACAGTTTT CTGGTCAACA TGTGTGATCT TTGTGTCTCC 
TTTTTGCCAA 
 2821 GCACATTCTG ATTTTCTTGT TGGAACACAG GTCTAGTTTC TAAAGGACAA 
ATTTTTTGTT 
 2881 CCTTGTCTTT TTTCTGTAAG GGACAAGATT TGTTGTTTTT GTAAGAAATG 
AGATGCAGGA 
 2941 AAGAAAACCA AATCCCATTC CTGCACCCCA GTCCAATAAG CAGATACCAC 
TTAAGATAGG 
 3001 AGTCTAAACT CCACAGAAAA GGATAATACC AAGAGCTTGT ATTGTTACCT 
TAGTCACTTG 
 3061 CCTAGCAGTG TGTGGCTTTA AAAACTAGAG ATTTTTCAGT CTTAGTCTGC 
AAACTGGCAT 
 3121 TTCCGATTTT CCAGCATAAA AATCCACCTG TGTCTGCTGA ATGTGTATGT 
ATGTGCTCAC 
 3181 TGTGGCTTTA GATTCTGTCC CTGGGGTTAG CCCTGTTGGC CCTGACAGGA 
AGGGAGGAAG 
 3241 CCTGGTGAAT TTAGTGAGCA GCTGGCCTGG GTCACAGTGA CCTGACCTCA 
AACCAGCTTA 
 3301 AGGCTTTAAG TCCTCTCTCA GAACTTGGCA TTTCCAACTT CTTCCTTTCC 
GGGTGAGAGA 
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 3361 AGAAGCGGAG AAGGGTTCAG TGTAGCCACT CTGGGCTCAT AGGGACACTT 
GGTCACTCCA 
 3421 GAGTTTTTAA TAGCTCCCAG GAGGTGATAT TATTTTCAGT GCTCAGCTGA 
AATACCAACC 
 3481 CCAGGAATAA GAACTCCATT TCAAACAGTT CTGGCCATTC TGAGCCTGCT 
TTTGTGATTG 
 3541 CTCATCCATT GTCCTCCACT AGAGGGGCTA AGCTTGACTG CCCTTAGCCA 
GGCAAGCACA 
 3601 GTAATGTGTG TTTTGTTCAG CATTATTATG CAAAAATTCA CTAGTTGAGA 
TGGTTTGTTT 
 3661 TAGGATAGGA AATGAAATTG CCTCTCAGTG ACAGGAGTGG CCCGAGCCTG 
CTTCCTATTT 
 3721 TGATTTTTTT TTTTTTTAAC TGATAGATGG TGCAGCATGT CTACATGGTT 
GTTTGTTGCT 
 3781 AAACTTTATA TAATGTGTGG TTTCAATTCA GCTTGAAAAA TAATCTCACT 
ACATGTAGCA 
 3841 GTACATTATA TGTACATTAT ATGTAATGTT AGTATTTCTG CTTTGAATCC 
TTGATATTGC 
 3901 AATGGAATTC CTACTTTATT AAATGTATTT GATATGCTAG TTATTGTGTG 
CGATTTAAAC 
 3961 TTTTTTTGCT TTCTCCCTTT TTTTGGTTGT GCGCTTTCTT TTACAACAAG CCTCTAGAAA 
 4021 CAGATAGTTT CTGAGAATTA CTGAGCTATG TTTGTAATGC AGATGTACTT 
AGGGAGTATG 
 4081 TAAAATAATC ATTTTAACAA AAGAAATAGA TATTTAAAAT TTAATACTAA 
CTATGGGAAA 
 4141 AGGGTCCATT GTGTAAAACA TAGTTTATCT TTGGATTCAA TGTTTGTCTT 
TGGTTTTACA 
 4201 AAGTAGCTTG TATTTTCAGT ATTTTCTACA TAATATGGTA AAATGTAGAG 
CAATTGCAAT 
 4261 GCATCAATAA AATGGGTAAA TTTTCTGACT TATGTGGCTG TTTTTGACTT 
CTGTTATAGG 




Supplemental Table S 2-1: Genes from microarray 
405 genes from one-way ANOVA of microarray experiment with fold change at least absolute 
value 1.5  











RNA, U6 small nuclear 658, 
pseudogene 0.0069 -2.47 
NRN1 neuritin 1 0.0008 -2.43 
RNU6-503P 
RNA, U6 small nuclear 503, 
pseudogene 0.0013 -2.39 
SULT1C4 
sulfotransferase family, cytosolic, 
1C, member 4 0.0136 -2.35 
RNA5SP237 RNA, 5S ribosomal pseudogene 237 0.0006 -2.32 
RNU7-195P 
RNA, U7 small nuclear 195 
pseudogene 0.0395 -2.26 
LINC00312 
long intergenic non-protein coding 
RNA 312 0.0006 -2.17 
RNU7-119P 
RNA, U7 small nuclear 119 
pseudogene 0.0253 -2.17 
RNU6-1337P 
RNA, U6 small nuclear 1337, 
pseudogene 0.0020 -2.13 
ZNF66 zinc finger protein 66 0.0268 -2.11 
ANKRD52 ankyrin repeat domain 52 0.0001 -2.10 
RNU6-853P 
RNA, U6 small nuclear 853, 
pseudogene 0.0057 -2.07 
TP53INP1 
tumor protein p53 inducible nuclear 
protein 1 0.0003 -2.01 
HOXA4 homeobox A4 0.0002 -1.99 
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MIR222 microRNA 222 0.0098 -1.98 
MIR4774 microRNA 4774 0.0088 -1.97 
LOC400043 uncharacterized LOC400043 0.0001 -1.97 
DAB2 
Dab, mitogen-responsive 
phosphoprotein, homolog 2 
(Drosophila) 0.0031 -1.96 
RNU6-466P 
RNA, U6 small nuclear 466, 
pseudogene 0.0224 -1.95 
EI24 etoposide induced 2.4 0.0009 -1.95 
RN7SKP78 
RNA, 7SK small nuclear 




LOC728392 uncharacterized LOC728392 0.0016 -1.91 
MERTK 
MER proto-oncogene, tyrosine 
kinase 0.0000 -1.91 
RNU6-684P 
RNA, U6 small nuclear 684, 
pseudogene 0.0224 -1.86 
MIR3975 microRNA 3975 0.0019 -1.86 
SLC16A2 
solute carrier family 16, member 2 
(thyroid hormone transporter) 0.0027 -1.86 
KRTAP19-1 keratin associated protein 19-1 0.0102 -1.85 
HOXB5 homeobox B5 0.0004 -1.81 
LGR5 
leucine-rich repeat containing G 
protein-coupled receptor 5 0.0063 -1.80 
RNU6-518P 
RNA, U6 small nuclear 518, 
pseudogene 0.0207 -1.80 
FAM89B 
family with sequence similarity 89, 





RNA5SP191 RNA, 5S ribosomal pseudogene 191 0.0106 -1.77 
TUBB4A tubulin, beta 4A class IVa 0.0077 -1.77 
RAB1A 
RAB1A, member RAS oncogene 
family 0.0014 -1.76 
HOXA2 homeobox A2 0.0014 -1.76 
RAB1B 
RAB1B, member RAS oncogene 
family 0.0001 -1.76 
RNU6-1327P 
RNA, U6 small nuclear 1327, 
pseudogene 0.0110 -1.75 
PICALM 
phosphatidylinositol binding 
clathrin assembly protein 0.0007 -1.75 
CD24 CD24 molecule 0.0096 -1.74 
MIR3139 microRNA 3139 0.0080 -1.74 
GPRC5B 
G protein-coupled receptor, class C, 
group 5, member B 0.0001 -1.74 
CYP4F30P 
cytochrome P450, family 4, 
subfamily F, polypeptide 30, 
pseudogene 0.0352 -1.74 
RNU6-1254P 
RNA, U6 small nuclear 1254, 
pseudogene 0.0034 -1.73 
MAP2K6 
mitogen-activated protein kinase 
kinase 6 0.0035 -1.73 
ELK3 
ELK3, ETS-domain protein (SRF 
accessory protein 2) 0.0009 -1.72 
NUP210 nucleoporin 210kDa 0.0007 -1.72 
OIP5 Opa interacting protein 5 0.0020 -1.72 






RNA, U6 small nuclear 66, 
pseudogene 0.0240 -1.70 
RNU6-564P 
RNA, U6 small nuclear 564, 
pseudogene 0.0464 -1.70 
BRWD3 
bromodomain and WD repeat 
domain containing 3 0.0002 -1.69 
RNU6-926P 
RNA, U6 small nuclear 926, 
pseudogene 0.0315 -1.69 
TMEM255A transmembrane protein 255A 0.0183 -1.69 
FN1 fibronectin 1 0.0089 -1.69 
LMCD1 LIM and cysteine-rich domains 1 0.0028 -1.69 
SMAGP small cell adhesion glycoprotein 0.0010 -1.69 
SMAD6 SMAD family member 6 0.0094 -1.69 
TCF7L1-IT1 TCF7L1 intronic transcript 1 0.0009 -1.69 
RNU7-57P 
RNA, U7 small nuclear 57 
pseudogene 0.0112 -1.68 
LRP2 
low density lipoprotein receptor-
related protein 2 0.0014 -1.67 
TMEM135 transmembrane protein 135 0.0014 -1.67 
CHD7 
chromodomain helicase DNA 




NOTCH3 notch 3 0.0038 -1.67 
RNA5SP123 RNA, 5S ribosomal pseudogene 123 0.0059 -1.67 
MIR320D1 microRNA 320d-1 0.0139 -1.66 
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PRKX protein kinase, X-linked 0.0046 -1.66 
RNU6-1056P 
RNA, U6 small nuclear 1056, 
pseudogene 0.0229 -1.66 
TGFBR1 
transforming growth factor, beta 
receptor 1 0.0005 -1.66 
SV2A synaptic vesicle glycoprotein 2A 0.0025 -1.66 
EPB41L5 
erythrocyte membrane protein band 
4.1 like 5 0.0002 -1.66 
DOCK4 dedicator of cytokinesis 4 0.0012 -1.65 
NID2 nidogen 2 (osteonidogen) 0.0056 -1.65 
RNY1P8 
RNA, Ro-associated Y1 pseudogene 
8 0.0365 -1.65 
RNU7-35P 
RNA, U7 small nuclear 35 
pseudogene 0.0079 -1.65 
H3F3B H3 histone, family 3B (H3.3B) 0.0001 -1.65 
MTA2 
metastasis associated 1 family, 
member 2 0.0004 -1.64 
ELOVL6 ELOVL fatty acid elongase 6 0.0004 -1.64 
RNU6-1079P 
RNA, U6 small nuclear 1079, 
pseudogene 0.0040 -1.64 
GALNT2 
polypeptide N-





RNA, U6 small nuclear 789, 
pseudogene 0.0449 -1.64 
UGT2B28 
UDP glucuronosyltransferase 2 






caspase activity and apoptosis 
inhibitor 1 0.0003 -1.63 
DDHD2 DDHD domain containing 2 0.0002 -1.63 
RNU6-1287P 
RNA, U6 small nuclear 1287, 
pseudogene 0.0118 -1.63 
GBA2 glucosidase, beta (bile acid) 2 0.0000 -1.63 
GALNT7 
polypeptide N-
acetylgalactosaminyltransferase 7 0.0000 -1.63 
CDK19 cyclin-dependent kinase 19 0.0002 -1.63 
RNU6-338P 
RNA, U6 small nuclear 338, 
pseudogene 0.0430 -1.62 
SMG7 
SMG7 nonsense mediated mRNA 
decay factor 0.0003 -1.62 
GLDC 
glycine dehydrogenase 




NEFL neurofilament, light polypeptide 0.0111 -1.62 
ZNF451 zinc finger protein 451 0.0005 -1.62 







FSTL1 follistatin-like 1 0.0000 -1.61 
RNU6-1216P 
RNA, U6 small nuclear 1216, 






activating transcription factor 7 
interacting protein 2 0.0003 -1.61 
SESN3 sestrin 3 0.0002 -1.61 
RASSF3 
Ras association (RalGDS/AF-6) 
domain family member 3 0.0006 -1.61 
GPC3 glypican 3 0.0184 -1.61 







MBNL3 muscleblind-like splicing regulator 3 0.0005 -1.60 
DAPK1-IT1 DAPK1 intronic transcript 1 0.0106 -1.59 
MIR520D microRNA 520d 0.0151 -1.59 








RNA, U7 small nuclear 97 
pseudogene 0.0047 -1.59 
MIR221 microRNA 221 0.0063 -1.59 
FAM223A 
family with sequence similarity 223, 
member A (non-protein coding) 0.0180 -1.59 
ELMO1 engulfment and cell motility 1 0.0008 -1.59 
B4GALT6 
UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 6 0.0000 -1.59 
ARHGEF6 
Rac/Cdc42 guanine nucleotide 
exchange factor (GEF) 6 0.0002 -1.59 
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COL14A1 collagen, type XIV, alpha 1 0.0132 -1.59 
OGDH 
oxoglutarate (alpha-ketoglutarate) 
dehydrogenase (lipoamide) 0.0039 -1.59 
ATP8A1 
ATPase, aminophospholipid 
transporter (APLT), class I, type 8A, 
member 1 0.0002 -1.59 
MURC muscle-related coiled-coil protein 0.0080 -1.58 
TMOD2 tropomodulin 2 (neuronal) 0.0018 -1.58 
RNA5SP160 RNA, 5S ribosomal pseudogene 160 0.0067 -1.58 
DPM2 
dolichyl-phosphate 
mannosyltransferase polypeptide 2, 
regulatory subunit 0.0018 -1.58 
CBL 
Cbl proto-oncogene, E3 ubiquitin 
protein ligase 0.0001 -1.58 
TPTEP1 
transmembrane phosphatase with 
tensin homology pseudogene 1 0.0004 -1.58 
DKFZP434L187 uncharacterized LOC26082 0.0153 -1.58 
MOB1B MOB kinase activator 1B 0.0026 -1.58 
CSK c-src tyrosine kinase 0.0003 -1.58 
ETS1 
v-ets avian erythroblastosis virus 
E26 oncogene homolog 1 0.0007 -1.58 
BCL11A 
B-cell CLL/lymphoma 11A (zinc 
finger protein) 0.0017 -1.57 
NRGN 
neurogranin (protein kinase C 






protein kinase II delta 0.0003 -1.57 
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RNU6-50P 
RNA, U6 small nuclear 50, 
pseudogene 0.0459 -1.57 
BMP2 bone morphogenetic protein 2 0.0016 -1.57 
ASIC1 
acid sensing (proton gated) ion 
channel 1 0.0032 -1.57 
ATP6V1D 
ATPase, H+ transporting, lysosomal 
34kDa, V1 subunit D 0.0095 -1.57 
DAG1 
dystroglycan 1 (dystrophin-
associated glycoprotein 1) 0.0029 -1.56 
LAMB1 laminin, beta 1 0.0017 -1.56 
CDHR3 cadherin-related family member 3 0.0016 -1.56 




SULF2 sulfatase 2 0.0068 -1.56 
TTLL5 
tubulin tyrosine ligase-like family 
member 5 0.0005 -1.56 
PPT1 palmitoyl-protein thioesterase 1 0.0104 -1.56 
HOXD10 homeobox D10 0.0005 -1.55 
ESYT1 
extended synaptotagmin-like protein 
1 0.0028 -1.55 
SSRP1 
structure specific recognition protein 
1 0.0019 -1.55 
GPC6 glypican 6 0.0015 -1.55 
LZIC 
leucine zipper and CTNNBIP1 
domain containing 0.0035 -1.55 









THRB-IT1 THRB intronic transcript 1 0.0039 -1.54 
PRPF38A pre-mRNA processing factor 38A 0.0018 -1.54 
MIR4653 microRNA 4653 0.0356 -1.54 
TSPY2 testis specific protein, Y-linked 2 0.0268 -1.54 
KIAA0100 KIAA0100 0.0039 -1.54 
CYP4F26P 
cytochrome P450, family 4, 
subfamily F, polypeptide 26, 





frequently rearranged in advanced 
T-cell lymphomas 2 0.0045 -1.54 
LOC100293704 
serine/arginine repetitive matrix 
protein 3-like 0.0027 -1.54 
RNU6-1206P 
RNA, U6 small nuclear 1206, 
pseudogene 0.0040 -1.54 
LPCAT3 
lysophosphatidylcholine 








ACLY ATP citrate lyase 0.0023 -1.53 
NENF neudesin neurotrophic factor 0.0020 -1.53 
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LOC101927248 uncharacterized LOC101927248 0.0228 -1.53 
MREG melanoregulin 0.0005 -1.53 
MAP3K8 
mitogen-activated protein kinase 
kinase kinase 8 0.0003 -1.53 
ZNF714 zinc finger protein 714 0.0053 -1.53 
STK39 serine threonine kinase 39 0.0009 -1.53 
MIR196B microRNA 196b 0.0248 -1.53 
PHC1 
polyhomeotic homolog 1 
(Drosophila) 0.0016 -1.53 
EMILIN3 elastin microfibril interfacer 3 0.0222 -1.52 
STARD9 
StAR-related lipid transfer (START) 
domain containing 9 0.0037 -1.52 
LOC101928700 uncharacterized LOC101928700 0.0303 -1.52 
NUS1 
NUS1 dehydrodolichyl diphosphate 




SATB2 SATB homeobox 2 0.0001 -1.52 
GPR52 G protein-coupled receptor 52 0.0097 -1.52 
TEAD2 TEA domain family member 2 0.0002 -1.52 
LOC220729 
succinate dehydrogenase complex, 
subunit A, flavoprotein (Fp) 
pseudogene 0.0052 -1.52 
MIR3908 microRNA 3908 0.0196 -1.52 
PAFAH1B2 
platelet-activating factor 
acetylhydrolase 1b, catalytic subunit 
2 (30kDa) 0.0133 -1.52 
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RNU6-719P 
RNA, U6 small nuclear 719, 
pseudogene 0.0014 -1.52 
LIN7C lin-7 homolog C (C. elegans) 0.0010 -1.52 
ST8SIA6 
ST8 alpha-N-acetyl-neuraminide 
alpha-2,8-sialyltransferase 6 0.0263 -1.51 
GALNT16 
polypeptide N-
acetylgalactosaminyltransferase 16 0.0040 -1.51 
TJP2 tight junction protein 2 0.0004 -1.51 
RNU4-9P 
RNA, U4 small nuclear 9, 
pseudogene 0.0046 -1.51 
MAF 
v-maf avian musculoaponeurotic 
fibrosarcoma oncogene homolog 0.0033 -1.51 
HIPK1 
homeodomain interacting protein 
kinase 1 0.0003 -1.51 
FGF13-AS1 FGF13 antisense RNA 1 0.0063 -1.51 
BAZ2A 
bromodomain adjacent to zinc 
finger domain, 2A 0.0004 -1.51 
ZBTB18 
zinc finger and BTB domain 
containing 18 0.0020 -1.51 
SCAMP1 
secretory carrier membrane protein 
1 0.0000 -1.51 
PTPN14 
protein tyrosine phosphatase, non-
receptor type 14 0.0002 -1.51 
ATP9A ATPase, class II, type 9A 0.0022 -1.51 
RNU6-1003P 
RNA, U6 small nuclear 1003, 
pseudogene 0.0141 -1.51 
SNORA70F 
small nucleolar RNA, H/ACA box 
70F 0.0260 -1.51 
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ROR1 
receptor tyrosine kinase-like orphan 
receptor 1 0.0010 -1.51 
MIR374B microRNA 374b 0.0126 -1.50 
OR5H6 
olfactory receptor, family 5, 
subfamily H, member 6 
(gene/pseudogene) 0.0211 -1.50 
N4BP1 NEDD4 binding protein 1 0.0013 -1.50 
FAM117B 
family with sequence similarity 117, 
member B 0.0000 -1.50 
GM2A GM2 ganglioside activator 0.0062 -1.50 
RNU7-155P 
RNA, U7 small nuclear 155 
pseudogene 0.0302 1.50 
VWA9 
von Willebrand factor A domain 
containing 9 0.0083 1.50 
FTL ferritin, light polypeptide 0.0001 1.50 
TMEM254 transmembrane protein 254 0.0034 1.50 
HIST1H2BM histone cluster 1, H2bm 0.0212 1.50 
NEU1 sialidase 1 (lysosomal sialidase) 0.0187 1.50 
UHMK1 
U2AF homology motif (UHM) 
kinase 1 0.0005 1.50 
MS4A18 
membrane-spanning 4-domains, 





proline rich Gla (G-carboxyglutamic 
acid) 4 (transmembrane) 0.0050 1.51 
RNU6-1032P 
RNA, U6 small nuclear 1032, 
pseudogene 0.0194 1.51 
TMPO-AS1 TMPO antisense RNA 1 0.0001 1.51 
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MAP2 microtubule-associated protein 2 0.0136 1.51 
METTL23 methyltransferase like 23 0.0006 1.51 
SEPSECS 
Sep (O-phosphoserine) tRNA:Sec 
(selenocysteine) tRNA synthase 0.0019 1.52 
LOC102723724 uncharacterized LOC102723724 0.0173 1.52 
USP46-AS1 USP46 antisense RNA 1 0.0147 1.52 
HIST1H2AJ histone cluster 1, H2aj 0.0002 1.52 
ASS1 argininosuccinate synthase 1 0.0109 1.52 
UBE2D1 
ubiquitin-conjugating enzyme E2D 






solute carrier family 9, subfamily B 
(NHA1, cation proton antiporter 1), 
member 1 pseudogene 3 0.0335 1.52 
RNA5SP253 RNA, 5S ribosomal pseudogene 253 0.0058 1.53 




XBP1 X-box binding protein 1 0.0206 1.53 
PEA15 
phosphoprotein enriched in 
astrocytes 15 0.0007 1.53 
EGF epidermal growth factor 0.0067 1.53 
RNU6-841P 
RNA, U6 small nuclear 841, 




MIR509-3 microRNA 509-3 0.0328 1.54 
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RNA5SP318 RNA, 5S ribosomal pseudogene 318 0.0116 1.54 
SPINK1 
serine peptidase inhibitor, Kazal 
type 1 0.0342 1.54 
NMI N-myc (and STAT) interactor 0.0032 1.54 
MOBP 
myelin-associated oligodendrocyte 
basic protein 0.0025 1.54 
C10orf107 
chromosome 10 open reading frame 
107 0.0491 1.54 
MIR4521 microRNA 4521 0.0033 1.54 
FLT3LG fms-related tyrosine kinase 3 ligand 0.0142 1.54 
GNAT2 
guanine nucleotide binding protein 
(G protein), alpha transducing 
activity polypeptide 2 0.0400 1.54 
KPNA5 
karyopherin alpha 5 (importin alpha 
6) 0.0010 1.54 
SNORA32 
small nucleolar RNA, H/ACA box 
32 0.0141 1.55 
WDR78 WD repeat domain 78 0.0016 1.55 
LOC102724897 uncharacterized LOC102724897 0.0338 1.55 
SOX30 
SRY (sex determining region Y)-
box 30 0.0119 1.55 
RNU6-1136P 
RNA, U6 small nuclear 1136, 
pseudogene 0.0160 1.55 
RNA5SP275 RNA, 5S ribosomal pseudogene 275 0.0243 1.55 
LINC00467 
long intergenic non-protein coding 
RNA 467 0.0011 1.55 
CCDC110 coiled-coil domain containing 110 0.0201 1.55 
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RNU6-1069P 
RNA, U6 small nuclear 1069, 
pseudogene 0.0341 1.56 
FAM206A 
family with sequence similarity 206, 
member A 0.0053 1.56 
RNU1-46P 
RNA, U1 small nuclear 46, 
pseudogene 0.0382 1.56 
IGFBP7 
insulin-like growth factor binding 
protein 7 0.0326 1.56 
ANKEF1 
ankyrin repeat and EF-hand domain 
containing 1 0.0045 1.56 
AGMAT agmatinase 0.0000 1.57 
RNU6-381P 
RNA, U6 small nuclear 381, 
pseudogene 0.0180 1.57 
HIST2H4B histone cluster 2, H4b 0.0054 1.57 
PSAT1 phosphoserine aminotransferase 1 0.0330 1.57 
OR2B6 
olfactory receptor, family 2, 
subfamily B, member 6 0.0016 1.58 
RNF122 ring finger protein 122 0.0190 1.58 
ELAVL3 
ELAV like neuron-specific RNA 
binding protein 3 0.0343 1.58 
C11orf1 
chromosome 11 open reading frame 
1 0.0007 1.58 
SFR1 
SWI5-dependent homologous 
recombination repair protein 1 0.0040 1.59 
MIR4527 microRNA 4527 0.0343 1.59 
RNU6-620P 
RNA, U6 small nuclear 620, 
pseudogene 0.0177 1.59 
CPA2 carboxypeptidase A2 (pancreatic) 0.0119 1.59 
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VTRNA1-3 vault RNA 1-3 0.0118 1.59 
C2orf74 
chromosome 2 open reading frame 
74 0.0089 1.59 
SESN2 sestrin 2 0.0010 1.60 
RNA5SP418 RNA, 5S ribosomal pseudogene 418 0.0291 1.60 
C2orf78 
chromosome 2 open reading frame 
78 0.0256 1.60 










RNA, U7 small nuclear 197 
pseudogene 0.0017 1.62 
E2F8 E2F transcription factor 8 0.0123 1.62 
PPP1R15A 
protein phosphatase 1, regulatory 
subunit 15A 0.0088 1.62 
RNU6-239P 
RNA, U6 small nuclear 239, 
pseudogene 0.0187 1.62 
RNU1-21P 
RNA, U1 small nuclear 21, 
pseudogene 0.0021 1.62 
SNX10 sorting nexin 10 0.0006 1.62 
PRTG protogenin 0.0004 1.62 
SCML2 
sex comb on midleg-like 2 
(Drosophila) 0.0030 1.63 
RNA5SP112 RNA, 5S ribosomal pseudogene 112 0.0197 1.63 
ATF3 activating transcription factor 3 0.0121 1.63 
67 
UCHL1-AS1 
UCHL1 antisense RNA 1 (head to 
head) 0.0170 1.64 
FAM74A7 
family with sequence similarity 74, 
member A7 0.0020 1.64 
TMEM27 transmembrane protein 27 0.0001 1.64 





long intergenic non-protein coding 
RNA 410 0.0266 1.65 
HSD17B14 
hydroxysteroid (17-beta) 




CLDN1 claudin 1 0.0007 1.65 
TMEM144 transmembrane protein 144 0.0029 1.65 
PARP16 
poly (ADP-ribose) polymerase 
family, member 16 0.0005 1.65 
RN7SKP228 
RNA, 7SK small nuclear 










HHLA3 HERV-H LTR-associating 3 0.0120 1.65 




RNA5SP27 RNA, 5S ribosomal pseudogene 27 0.0168 1.66 
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HIST2H3D histone cluster 2, H3d 0.0046 1.67 
PPP1R1C 
protein phosphatase 1, regulatory 
(inhibitor) subunit 1C 0.0327 1.67 
TMEM31 transmembrane protein 31 0.0106 1.67 
HIST1H2BJ histone cluster 1, H2bj 0.0074 1.67 
CPS1 
carbamoyl-phosphate synthase 1, 
mitochondrial 0.0035 1.67 
MICB 
MHC class I polypeptide-related 
sequence B 0.0004 1.67 
LOC101927902 uncharacterized LOC101927902 0.0243 1.67 







SLC10A5 solute carrier family 10, member 5 0.0048 1.68 
SPX spexin hormone 0.0427 1.69 
SYPL1 synaptophysin-like 1 0.0028 1.70 
HIST1H1T histone cluster 1, H1t 0.0010 1.70 
ANKRD1 
ankyrin repeat domain 1 (cardiac 
muscle) 0.0031 1.71 
ANXA9 annexin A9 0.0199 1.71 
DCT dopachrome tautomerase 0.0070 1.72 
LOC101928868 atherin-like 0.0275 1.72 







pyrophosphorylase 1 like 1 0.0006 1.73 
CHAC1 
ChaC glutathione-specific gamma-
glutamylcyclotransferase 1 0.0460 1.73 
LOC100507336 uncharacterized LOC100507336 0.0258 1.74 
RNU6-715P 
RNA, U6 small nuclear 715, 
pseudogene 0.0074 1.75 





HIV-1 Tat interactive protein 2, 
30kDa 0.0010 1.76 
SLC16A6 solute carrier family 16, member 6 0.0141 1.77 
MAL2 
mal, T-cell differentiation protein 2 
(gene/pseudogene) 0.0066 1.77 
COX7BP1 
cytochrome c oxidase subunit VIIb 
pseudogene 1 0.0201 1.77 
NBEAP1 neurobeachin pseudogene 1 0.0175 1.79 
SLC3A2 
solute carrier family 3 (amino acid 
transporter heavy chain), member 2 0.0020 1.81 




BLVRB biliverdin reductase B 0.0001 1.83 
LOC729083 uncharacterized LOC729083 0.0055 1.83 
MMP12 matrix metallopeptidase 12 0.0116 1.83 
CTH cystathionine gamma-lyase 0.0205 1.84 
STMND1 stathmin domain containing 1 0.0015 1.84 
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GADD45B 
growth arrest and DNA-damage-
inducible, beta 0.0203 1.84 
LMLN 
leishmanolysin-like 





family with sequence similarity 129, 
member A 0.0036 1.88 
LOC101929174 uncharacterized LOC101929174 0.0443 1.89 
USP17L23 
ubiquitin specific peptidase 17-like 
family member 23 0.0046 1.90 




5 (putative) 0.0019 1.90 
RNU6-287P 
RNA, U6 small nuclear 287, 
pseudogene 0.0030 1.91 
RFPL3S RFPL3 antisense 0.0355 1.92 
CCR4 chemokine (C-C motif) receptor 4 0.0397 1.92 
DHRS2 
dehydrogenase/reductase (SDR 
family) member 2 0.0011 1.93 
SLC7A5 
solute carrier family 7 (amino acid 
transporter light chain, L system), 
member 5 0.0021 1.95 
RNU6-1178P 
RNA, U6 small nuclear 1178, 




DDIT3 DNA-damage-inducible transcript 3 0.0038 1.99 
RNU6-755P 
RNA, U6 small nuclear 755, 
pseudogene 0.0461 1.99 
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LOC100506790 uncharacterized LOC100506790 0.0128 2.02 
MPZL3 myelin protein zero-like 3 0.0002 2.07 
SLC6A9 
solute carrier family 6 
(neurotransmitter transporter, 








secretory leukocyte peptidase 




CLU clusterin 0.0011 2.15 




LOC102724810 uncharacterized LOC102724810 0.0013 2.23 
LIPH lipase, member H 0.0004 2.23 
TLR3 toll-like receptor 3 0.0004 2.24 
SPANXN3 SPANX family, member N3 0.0123 2.24 
RFPL4AL1 ret finger protein-like 4A-like 1 0.0213 2.26 
USP17L15 
ubiquitin specific peptidase 17-like 
family member 15 0.0039 2.27 
NUPR1 
nuclear protein, transcriptional 
regulator, 1 0.0084 2.36 
MIR4525 microRNA 4525 0.0010 2.36 
LINC00624 
long intergenic non-protein coding 
RNA 624 0.0024 2.39 
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MIR7-3HG MIR7-3 host gene 0.0199 2.43 
HIST1H4H histone cluster 1, H4h 0.0033 2.46 
BEST1 bestrophin 1 0.0132 2.53 
RNU2-62P 
RNA, U2 small nuclear 62, 
pseudogene 0.0269 2.73 
USP17L5 
ubiquitin specific peptidase 17-like 
family member 5 0.0022 2.80 
SLC7A11 
solute carrier family 7 (anionic 
amino acid transporter light chain, 
xc- system), member 11 0.0049 2.96 
RNA5SP141 RNA, 5S ribosomal pseudogene 141 0.0126 3.25 
ACTBL2 actin, beta-like 2 0.0007 4.64 
CEACAMP7 
carcinoembryonic antigen-related 
cell adhesion molecule pseudogene 
7 0.0016 4.84 
RNA5SP494 RNA, 5S ribosomal pseudogene 494 0.0080 5.20 
 
Supplemental Table S 2-2: siRNA for gene validation  
Gene siRNA ID Sense sequence 
HIPKK1 S47549 GCUCAAUACAGUGCACAAUtt 
EMILIN3 S40280 GCACAGUACUCAGACCCAAtt 
FRAT2 S23745 UAACAAUACUUGAAAACUAtt 
LIN7C S30740 AGAGAUAUUUGUAGAGCAAtt 
MURC S51226 CCUGUCGAGUGUUACAGAAtt 
















Chapter 3 Stable knockout of HIPK1 improves recombinant 
protein expression more than stable over-expression of mir-22-3p 
Abbreviations: CRISPR, Clustered Regularly Interspaced Short Palindromic Repeats; HEK293, 
Human Embryonic Kidney Cells; HIPK1, Homeodomain-Interacting Protein Kinase 1; mir, 
microRNA; Luc-HEK, Luciferase expressing Human Embryonic kidney cells; SEAP, secreted 
alkaline phosphatase 
3.1 Summary  
Stable cell lines give the ability to continuously produce a protein without having to repeatedly 
engineer the genome. In the previous chapter, the fact that mir-22-3p increases recombinant 
protein expression was used along with a high-throughput siRNA screen and a microarray 
analysis to identify Homeodomain-interacting Protein Kinase 1 (HIPK1) as a target of mir-22 that 
when repressed, improves expression of both an intercellular protein and a secreted protein. In the 
work described in this chapter, stable HEK293 cell lines over expressing mircroRNA mir-22 were 
compared with stable HEK293 cell lines with HIPK1 knocked out with CRISPR/Cas9 for their 
ability to improve protein expression. In the model case of luciferase, the over-expressing mir-22 
improved overall expression 2.4-fold while the HIPK1 knockout improved overall expression 
4.7-fold. 
3.2 Introduction  
As previously discussed, recombinant protein expression is the process of manipulating gene 
expression to produce a specific protein for use in biotherapeutics, research, crops, and other 
fields [134]. HEK 293 cells, while not as common as CHO cells, due to their platform 
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technologies for selection of high producing clones [135], are increasingly being used for more 
complex proteins [13, 14]. There are several methods available for adding recombinant proteins 
to cells for production either stably or transiently [136]. Stable transfections or transductions 
integrate the genetic material into the host cell genome and typically have a selectable marker of 
some sort, an antibiotic or a detectable reporter gene [137]. Stable cell lines give the ability to 
continuously produce a protein without having to repeatedly engineer the genome [138]. 
Chapters one and two introduced microRNA and it’s function as a short non-coding regulatory 
RNA about 20-25 nucleotides long. It is transcribed in the nucleus as a double-stranded primary-
microRNA where it is processed by Drosha to become the hairpin pre-microRNA. After being 
exported from the nucleus to the cytoplasm by the Exportin-5, they are cleaved by Dicer into 
mature microRNA after which one strand enters the RNA induced silencing complex (RISC) 
where the microRNA imperfectly binds to mRNA to repress gene expression [139-141]. Chapter 
one described the recent use of microRNAs for improving recombinant protein expression in 
mammalian cells, often developed into stable, high producing cell lines [1, 24, 26, 27]. For 
example, the stable over-expression of mir-17 was shown to increase specific and overall EpoFc 
titer in CHO cells [55] and stable depletion of mir-7 using mir-7 sponge decoy vectors was shown 
to improve the yield of a secreted protein [34]. MicroRNAs have the advantage of a reduced 
metabolic load in the host cell compared to transcriptional factor regulatory proteins or kinases 
due to the lack of burden on translational machinery so the cell resources can be used toward 
recombinant protein production. 
The Clustered Regularly Interspaced Short Palindromic Repeats/Crispr Associated Protein 9 
(CRISPR/Cas9) system is a gene editing system that originated as a bacterial and archaeal 
immune system but has been adapted for use in eukaryotes [142]. The CRISPR/Cas9 system uses 
guide RNA (gRNA) to guides the Cas9 nuclease to cleave the DNA at a specific target near an 
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NGG protospacer adjacent motif (PAM sequence). Then the cells' repair machinery repairs the 
broken DNA [143-145]. This mechanism can be used to engineer genes through including 
knocking out a gene. There are many commercial products available for CRISPR/Cas Nuclease 
RNA-guided Genome editing with a variety of delivery methods [146]. These include a 
CRISPR/Cas9 lentivirus that gives efficient chromosomal integration of the CRISPR components 
for long term stability with fewer off-target effects [147]. CRISPR interference (CRISPRi) has 
been used to improve recombinant protein expression in CHO cells, suppressing dhfr 
transcription caused extra selective pressure on the cells improving the productivity 2.3 fold 
[148]. CRISPR gives the ability to knockout a single gene without as many of the off-target 
effects that may be seen from microRNA and may therefore be better for protein expression.  
In a previous high-throughput microRNA screen of 875 human microRNAs, mir-22 was 
identified as a top microRNA for improving multiple protein types including two membrane 
proteins, a secreted protein and a reporter protein [43]. This was then used along with a high-
throughput siRNA screen [73] and a microarray analysis [2] in chapter two to identify 
Homeodomain-interacting Protein Kinase 1 (HIPK1) as a target of mir-22 that when repressed, 
improves both a reporter protein, firefly luciferase, and a secreted protein expression, glypican-3 
hFc fusion protein. In this chapter, stable HEK293 cell lines over expressing mir-22 were 
compared with stable HEK293 cell lines with HIPK1 knocked out with CRISPR/Cas9 for 
improving protein expression. In the model case of luciferase, the over-expressing mir-22 





3.3 Materials and Methods 
3.3.1 Cell lines and cultures 
A CMV-LUC2-HygroHEK293 cell line (Luc-HEK cells) constitutively expressing Photinus 
pyralis firefly luciferase was purchased from Promega (Madison, WI). A Human Embryonic 
Kidney (HEK293) cell line was purchased from ATCC (Manassas, VA). Anchorage-dependent 
cells were maintained in 10% Fetal Bovine Serum (FBS, Atlanta Biologicals, Flowery Branch, 
GA) Dulbecco's Modified Eagle Medium (DMEM10, Gibco, Gaithersburg, MD) and cells 
adapted to suspension were maintained in Freestyle medium (Gibco) on a shaker at 130 rpm. 
Experiments were completed with cells between passage number 3 and 50. Cells were kept in a 
humidified incubator set at 5% CO2 and 37°C. 
3.3.2 Stable microRNA-22 transfection 
HEK293 cells and Luc-HEK cells were stably transfected with the pCMV-MIR-22 vector 
(Origene Technologies, Rockville, MD) (see Supplemental Figure S 3-1) containing a GFP 
marker and antibiotic resistance. As a negative control, cells were transfected with a pCMV-mir 
negative control vector (Origene Technologies) not containing the microRNA portion. Cells were 
seeded at 1.5 x105 cells per well in 500 µL of DMEM10 in a 24-well plate. The following day, 1 
µL Lipofectamine3000 (Life Technologies, Waltham, MA), 1 µL P3000 and 500 ng plasmid 
were added to the cells in 50 µL of OptiMEM (Gibco) following the manufacturer’s protocol. 
Cells were selected with G418 (Life Technologies) and clones were selected with Fluorescence-
activated cell sorting (FACS) single cell sorting. 
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3.3.3 Luciferase activity, western blot, and cell viability assays 
Luciferase expressing cells were harvested and 100 µl were transferred to 96-well plate for 
luciferase and cell viability assays. The cells in the 96-well plate were measured for luciferase 
with ONE-Glo™ Reagent (Promega) and for viability with CellTiter-Glo Reagent (Promega), 
using a SpectraMax i3 plate reader (Molecular Devices, San Jose, CA) according to the 
manufacturer protocol. The "per cell luciferase production" was calculated from overall luciferase 
activity and viable cell number. P-values were calculated with a two-sample unpaired t-Test 
assuming unequal variances with the Data analysis package in Excel. For the western blot, 
luciferase expressing cells were transfected as above in duplicates. Seventy-two hours after 
transfection cells were washed with cold PBS and lysed using RIPA buffer with protease and 
phosphatase inhibitor cocktail (Thermo Fisher Scientific, Waltham, MA). Lysates from the 
duplicate wells were combined and diluted with PBS to equal concentrations. Proteins were 
separated with a NuPAGE 4-12% bis-tris gel (Thermo Fisher Scientific) at 200 V for 50 min and 
transferred to a nitrocellulose membrane using the iBlot Gel Transfer System (Invitrogen, 
Carlsbad, CA) using P8 for 8 min. This was then used for immunodetection with mouse anti 
luciferase at a 1:1,500 dilution (Thermo Fisher Scientific) and mouse anti-β-actin at a 1:1,000 
(Sigma-Aldrich, St. Louis, MO) as primary antibodies and an HRP conjugated goat anti-mouse 
secondary antibody at a 1:5,000 (KPL, Milford, MA). Signals were detected with an ECL PLus 
chemiluminescence reagent (Thermo Fisher Scientific). The membrane was stripped between 
primary antibodies using Restore™ plus western blot stripping buffer (Thermo Fisher Scientific). 
3.3.4 RNA and DNA extraction 
Total RNA, including microRNA, was extracted from the cell pellets with the miRNEasy kit 
(Qiagen, Hilden, Germany) with DNase Digestion (Qiagen) following the manufacturer’s 
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protocol with an extra RPE buffer (Qiagen) wash. Genomic DNA was extracted from the cell 
pellets using the DNEasy Blood and Tissue Kit (Qiagen) following the manufacturer’s protocol. 
The extraction processes involved lysing the cells and purifying with a spin column. RNA and 
DNA concentration and quality were determined with the NanoDrop 2000 or NanoDropOne 
Spectrophotometer (Thermo Fisher Scientific).  
3.3.5 qRT PCR 
For microRNA expression analysis, miScript PCR starter kit (Qiagen) was used with the mir-22-
3p miScript Primer Assay (Qiagen) following the manufacturer’s instructions. Briefly, 100 ng 
RNA was transcribed to cDNA by incubating with the Reverse Transcriptase mixed with high 
flex buffer. Then the qPCR was performed using the SYBR green mix, primer assay and 
universal primer with the prescribed conditions and measured on the 7500 Fast Real Time PCR 
System (Applied Biosystems, Foster City, CA). Relative gene expression was calculated using 
the 2-∆∆CT method with human RNU6B as the reference gene. For SEAP and Luciferase 
expression analysis, the Maxima First strand cDNA synthesis (Thermo Fisher Scientific) and the 
Sybr Green (Applied Biosystems) were used according to manufacturer’s instructions with 500 
ng of RNA and measured on the CFX96 Touch (Bio-Rad Laboratories, Hercules, CA). Relative 
gene expression was calculated using the 2-∆∆CT method with human GAPDH as the reference 
gene. Primer sequences can be found in Supplemental Table S 3-1.  
3.3.6 Growth Studies 
Anchorage dependent cells were seeded in 6 wells of a 6 well plate at 150,000 cells per well. 
Each day, the supernatant was collected for glucose and lactate measurements using the YSI 
(Yellow Springs Instrument Co.). The cells were harvested using 0.5 mL Trypsin-EDTA (Gibco) 
and then combined with another 1.5 mL fresh media for measuring cell count with the Cedex 
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HiRes (Roche, Indianapolis, IN). Suspension cells were seeded at 15,000 cells per mL in a 125-
mL shake flask. A 1.5 mL sample was taken daily and measured for glucose, lactate, cell count, 
luciferase and cell viability as described above.  
3.3.7 Stable HIPK1 knockout  
HEK293 cells and Luc-HEK cells were transduced using a lentiviral CRISPR/Cas9 system 
containing a GFP marker and antibiotic resistance (Sigma-Aldrich) to knockout HIPK1 (see 
Supplemental Figure S 3-2). A negative control was created using the lentiviral CRISPR/Cas9 
system with non-targeting control (Sigma-Aldrich). Cells were seeded at 5,000 cells per well in a 
96 well plate. The following day enough lentivirus was added to the cells for a target MOI of 5, in 
50 µL media following manufacturer’s protocol. Cells were maintained with puromycin (Life 
Technologies) pressure and clones were selected with FACS single cell sorting.  
3.3.8 Sequencing Analysis 
The section of HIPK1 that was targeted by the gRNA of the CRISPR lentivirus was amplified 
from the genomic DNA using PCR with Phusion High Fidelity PCR master mix (New England 
Biolabs, Ipswich, MA) following the manufacturer’s protocol. The PCR primers are listed in 
Supplemental Table S 3-1. For each sample, 2-50 µL PCR reactions were purified using the 
QIAquick gel extraction kit (Qiagen) after a gel electrophoresis in a 0.8% agarose gel. The Center 





3.3.9 TOPO cloning 
Using the same PCR amplification and gel extraction described in the sequencing analysis, PCR 
products with blunt ends were produced, cloned into the pCR-Blunt-TOPO vector (Invitrogen, 
Carlsbad, CA) and transformed into competent E. coli following the manufacturer 
recommendations. Briefly the PCR products were ligated into the TOPO vector with a salt buffer. 
One shot competent E. coli (Invitrogen) were thawed and transformed with 2 µL of ligation 
mixture by heat shocking for 2 min, then growing for an hour in SOC medium at 225 rpm and 
37°C. They were then spread on LB plates with 50 µg/mL kanamycin and incubated overnight at 
37°C. For each sample, 10 colonies were selected, cultured overnight in 2 mL of LB media with 
50 µg/ml kanamycin and then the plasmids were extracted with the QIAprep Spin Miniprep kit 
(Qiagen) and sequenced by the Center for Biologics Evaluation and Research at the Food and 
Drug Administration. 
3.3.10 Surveyor Assay 
To confirm mutation in the HIPK1 knockout cells, the Surveyor Mutation Detection Kit for 
Standard Gel Electrophoresis (Integrated DNA Technologies, Coralville, IA) was used following 
the manufacturer’s instructions. Briefly, PCR amplicons were prepared using genomic DNA from 
each Luc-HEK cells and Luc-HEK-HIPK1 KO cells isolated as described above. The primers are 
listed in Supplemental Table S 3-1. Hetero- and homo-duplexes were formed by hybridizing 
DNA either unmixed, or mixed equal amounts of Luc-HEK and Luc-HEK-HIPK1 KO then 




3.3.11 Secreted alkaline phosphatase (SEAP) activity transfection and activity assay  
Secreted alkaline phosphatase (SEAP) transfections were performed in 24-well plates with a 
pSEAP plasmid (Invivogen, San Diego, CA). Three different cultures (biological triplicates) of 
cells were transfected. HEK-Luc or HEK293 cells including the mir-22 and HIPK1 KO cells 
were seeded at 2 x105 cells per well in 500 µL of DMEM10. The following day, 100 ng of 
plasmid was added with 1.5 µL of lipofectamine 2000 and 50 µL of OptiMEM following the 
manufacturer’s protocol. The plates were then incubated at 5% CO2 and 37°C. Once the cells 
were confluent, the supernatant was collected for activity assay and the cells were harvested, 
counted, and collected for RNA extraction. P-values were calculated with a two-sample unpaired 
t-Test assuming unequal variances with the Data analysis package in Excel.  
To measure the SEAP, the supernatant was collected from the transfected cells. The cells were 
harvested and count for each sample was measured using the Cedex. The SEAP was measured 
with the QUANTI-Blue assay (Invivogen) following manufacturer recommendations. For each 20 
µL of supernatant was added to a 96 well clear bottom plate in triplicate. Then 200 µL of pre-
warmed QUANTI-Blue was added to the well. The plate was then incubated at 37°C for 15 min 
prior to reading the absorption at 640 nm with the SpectraMax plate reader (Molecular Devices). 
3.3.12 Adaption to suspension 
Anchorage dependent cells were gradually adapted to suspension in a stepwise manner. Initially 
decreasing the concentration of the medium from DMEM10 and adapting the cells to a 
chemically defined Freestyle (Gibco) medium, 20% each passage, keeping the concentration the 
same for multiple passages if needed for the adaption. Once the cells were adapted to chemically 
defined media, the cells were added to non-tissue culture treated T flasks and put on a shaker at 
125 RMP and finally to a 125-mL shake-flask. 
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3.4. Results 
3.4.1 Effect of stable mir-22 over-expression on luciferase expression 
To demonstrate that stably over-expressing mir-22 improves protein expression, cells 
constitutively expressing a reporter protein, firefly luciferase, were stably transfected with a mir-
22 plasmid or a negative control vector. Cells over-expressing the mir-22 plasmid were selected 
with antibiotic and then sorted with FACSs for single cell cloning. The best clone was selected 
based on luciferase and cell viability assay and compared to the parental luciferase cells (Luc-
HEK), a mir-22 expressing pool and the negative control, Figure 3-1 A. Overall luciferase 
expression is 2.4-fold higher than the Luc-HEK and luciferase per cell is 2.7- fold higher than that 
of the parental Luc-HEK cells and 2.0-fold higher than the negative control. The unsorted pool 
over-expressing mir-22 was also higher producing than both the negative control and the 
parental cells. The western blot, also demonstrated that the luciferase protein was 
increased Figure 3-1 B. Quantitative PCR was performed to confirm the over-expression of mir-
22, Figure 3-1 C. Both the pre-cursor mir-22 and the mature mir-22-3p are over-expressed 
compared to the negative control and the parental Luc-HEK cells. A growth study was performed 
to compare the cell viability and cell growth, which were slightly lower in the cells with over-
expressed mir-22 (Supplemental Figure S 2-1).  
3.4.2 Effect of stable HIPK1 knockout on luciferase expression 
To determine if the stable knockout of HIPK1 improves protein expression, the CRISPR/Cas9 
lentiviral system was used to transduce luciferase expressing HEK cells. The cells were then put 
under antibiotic pressure and selected with FACS. The best clone was selected using overall 
luciferase and cell viability assays, Figure 3-2A. The best clone had an overall luciferase 
expression 4.7-fold higher than the parental and specific luciferase per cell expression 5.3-fold 
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higher than the parental Luc-HEK cells. The HIPK1 KO clones also had a specific productivity 
3.6-fold higher than the negative control. The unsorted pool was 1.5-fold higher than the Luc-
HEK cells and 1.3-fold higher than the negative control. The western blot (Figure 3-2B) also 
demonstrates improved luciferase in the HIPK1 KO. To confirm the HIPK1 gene was mutated, 
the section targeted by the gRNA was amplified with PCR, gel purified and sequenced 
(Supplemental Figure S 3-4A). Then the topo cloning and sequencing was performed to confirm a 
double stranded break (Supplemental Figure S 3-4B). A surveyor assay was also performed to 
confirm a mutation (Supplemental Figure S 3-4C). A growth study was performed to compare 
the cell viability and cell growth, again the parental cells grew faster than the HIPK1 KO cells 
(Supplemental Figure S 3-5). 
3.4.3 Effect of stable mir-22 over expression and stable HIPK1 knockout on SEAP 
The determine if the effect of improved expression extends to additional protein, the cells were 
transiently transfected with secreted alkaline phosphatase (SEAP). The SEAP expression was 
improved with the HIPK1 KO by 1.35-fold SEAP per cell (Figure 3-3 A), however the 
overexpressing mir-22 cells showed a decrease in both overall and specific production of SEAP 
compared to the parental luciferase cells. This is likely due to the improved viable cell density in 
the mir-22 overexpressing cells after the transfection compared to the parental luciferase cells. 
SEAP is a secreted protein and HIPK1 functions as a transcription regulator, therefore, the 
mRNA levels were also examined with qRT-PCR (Figure 3-3B) which showed a similar pattern 
to the activity assay. 
3.4.4 Adaption to anchorage independent culture conditions 
Since suspension cells required less footprint, are easier to measure and can be grown in a 
bioreactor, the over-expressing mir-22 anchorage-dependent clone and the HIPK1 knockout clone 
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along with the parental Luc-HEK cell line were adapted to suspension culture in a stepwise 
process Figure 3-4 shows the comparison of cell viability, cell growth comparison, glucose, and 
lactate comparison.  
3.4.5 Effect of stable mir-22 over expression and stable HIPK1 knockout on HEK293 cells 
transfected with SEAP 
HEK-293 cells stably over-expressing mir-22 and with HIPK1 stably knocked out were 
transiently transfected with secreted alkaline phosphatase (SEAP) and compared to parental 
HEK293 cells transfected with SEAP. Both the 293-mir-22 cells and 293 HIPK1 KO cells were 
approximately 1.7-fold higher SEAP per cell than the HEK293 however, with p-values >0.05, 
they are not significant. (Figure 3-5).  
3.5 Discussion 
Creating high amounts of recombinant protein is useful for a variety of purposes including both 
industrial and research fields. Improving protein expression by stable overexpression of 
microRNA has been successfully used in Chinese hamster ovary (CHO) cells [49, 50]. 
MicroRNAs are non-coding RNA and thus the translational burden of over-expression is reduced 
which make them advantageous for cell engineering [29]. However, since microRNAs regulate 
multiple genes [139, 140] there is the potential for some of the advantageously regulated genes to 
be balanced out by some genes that inhibit recombinant protein expression. Most microRNAs 
including mir-22 are not completely elucidated and while there are many predicted targets, most 
have not been validated [60, 61, 118]. For this reason, it could be argued that knocking down or 
knocking out a single gene that has been shown to improve recombinant protein expression is a 
better method. Here, the effects of a stable over-expressing of mir-22 and a stable knockout of 
HIPK1 were compared. 
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Mir-22 is an oncomir that has been extensively studied with its relationship to various cancers. It 
has been shown to influence cell growth, proliferation, and apoptosis [108, 149-152] which might 
have an effect on its ability to produce recombinant protein, however the studies show it can both 
enhance and inhibit both proliferation and apoptosis depending on its conditions. HIPK1 is a 
serine/threonine protein kinase that regulates transcription. It primarily regulates homeodomain 
transcription factors such as DAXX and myc [121, 124-126, 128] but it has been shown to 
regulate cell growth and apoptosis in mice [153]. In a previous study HIPK1 was shown to be a 
target of mir-22 [2].  
In this study, while both stable cell lines improved luciferase expression compared to the parental 
cell lines, the HIPK1 KO had a higher improvement of luciferase and improved SEAP production 
in the luciferase cells. The growth rates of both the microRNA over-expressing cells and the 
HIPK1 knockout cells were lower than those of the parental cell lines possibly suggesting some 
of their growth machinery has been redirected towards production. 
By using single cell isolation, there is risk of difference in productivity being due to a high 
producing clone independent of the intended change from transfection. A pool of mir-22 over 
expressing cells also shows improved expression, indicating the improvement is not just due to a 
clonal isolation effect, however, the pool of knockout HIPK1 did not show as much increased 
expression. This could indicate that the improvement is due to a clonal isolation effect but it 
could also be because there are many cells without a complete double stranded knockout in the 
pool. 
The results described in this chapter also demonstrate that while improvement in protein 
expression is possible using transient transfection of the stable overexpressed mir-22 or HIPK1 
KO, an increased improvement is gained from stable expression of both the recombinant protein 
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and either the over-expressed microRNA or the HIPK1 KO. This is likely due to the inefficient 
method for transient transfection.  
3.5.1 Conclusion 
Stable over-expression of microRNA 22 and stable knockout of HIPK1 are both good ways to 
improve recombinant protein expression in HEK293 cells. Knocking-out HIPK1 improves 
expression of recombinant protein better than by overexpressing microRNA-22 but the process of 
generating and confirming a CRISPR knockout is more time consuming. With advancements in 
CRISPR technology this may be streamlined and more efficient in the future. A knockout of a 
single gene allows for more understanding of what happens in the cell than overexpressing the 
microRNA. 
Contributions from collaborators: 
Laura Abaandou assisted with experimental design and construction of the CRISPR negative 
control.   
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Figures and Tables 
Figure 3-1: MicroRNA-22 overexpression in luciferase expressing HEK cells 
A) Luciferase, cell viability, and luciferase per cell, B) western blot and C) qPCR of Luc-HEK, 
Luc-HEK-mir-22, Luc-HEK-mir-22 pool, and Luc-HEK-mir-NC cells. Error bars represent 
Standard Error of the Mean (SEM) from triplicate measurements. * indicates P ≤ 0.05 relative to 







Figure 3-2: HIPK1 knockout in luciferase expressing HEK cells 
A) Luciferase, cell viability, and luciferase per cell and B) western blot for Luc-HEK, Luc-HEK-
HIPK1 KO, Luc-HEK-HIPK1 KO pool, and Luc-HEK-CRISPR-NC cells. Error bars represent 
Standard Error of the Mean (SEM) from triplicate measurements. * indicates P ≤ 0.05 and **** 






Figure 3-3: Effect of mir-22 and HIPK1 KO on SEAP expression in Luciferase expressing HEK 
cells  
A) SEAP, cell viability and SEAP per cell and B) qPCR for Luc-HEK, Luc-HEK-mir-22 and 
Luc-HEK-HIPK1-KO. Error bars represent Standard Error of the Mean (SEM) from triplicate 





Figure 3-4: Growth study of the suspension adapted cells  
A) Viable cell density, B) Viability, C) Glucose and D) Lactate as a function of time (days) for 
Luc-HEK, Luc-HEK-mir-22, and Luc-HEK-HIPK1 KO cells. 
 
Figure 3-5: Effect of mir-22 and HIPK1 KO on SEAP expression in 293 HEK cells 
SEAP, cell viability and SEAP per cell of HEK293, 293-mir-22 and 293-HIPK1-KO cells. Error 







Supplemental Figure S 3-1: mir-22 over-expression vector and mir-22 sequence 
 







Supplemental Figure S 3-2: Lentiviral Vector and gRNA sequence for HIPK1 knockout  
 
* from Sigma-Aldrich 
gRNA sequence: 
 
Supplemental Figure S 3-3: Growth study of the Luc-HEK-mir-22 cells  
A) Viable cell density, B) Viability, C) Glucose and D) Lactate as a function of time (days) for 
Luc-HEK and Luc-HEK-mir-22 cell 
 
 
Target ID gRNA sequence + PAM Species Gene Gene ID RefSeq Exon Nucleotide position in RefSeq
HS0000530261 GCTGTACCGATTGTACCCCAGG Human HIPK1 204851 NM_152696 9 2196
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Supplemental Figure S 3-4: HIPK1 Knockout verification 
A) Sequencing results from Luc-HEK and Luc-HEK HIPK1 knockout B) Luc-HEK TOPO 







C4       TCTGGATTCCCTGTGAGGATGGATAATGCTGTAC-----------------CCAGGCACC 
luc      TCTGGATTCCCTGTGAGGATGGATAATGCTGTACCGATTGTACC-------CCAGGCACC 
C7       TCTGGATTCCCTGTGAGGATGGATAATGCTGTAC-----------------CCAGGCACC 
C1       TCTGGATTCCCTGTGAGGATGGATAATGCTGTACCGATTGTACAATCGGTGCCAGGCACC 
C10      TCTGGATTCCCTGTTAGGATGGATAATGCTGTAC-----------------CCAGGCACC 
C9       TCTGGATTCCCTGTGAGGATGGATAATGCTGTAC-----------------CCAGGCACC 
C6       TCTGGATTCCCTGTGAGGATGGATAATGCTGTAC-----------------CCAGGCACC 
C8       TCTGGATTCCCTGTGAGGATGGATAATGCTGTAC-----------------CCAGGCACC 
C2       TCTGGATTCCCTGTGAGGATGGATAATGCTGTAC-----------------CCAGGCACC 
C3       TCTGGATTCCCTGTGAGGATGGATAATGCTGTAC-----------------CCAGGCACC 
C5       TCTGGATTCCCTGTGAGGATGGATAATGCTGTAC-----------------CCAGGCACC 
         ************** *******************                 ********* 
luc          ------ATTTCGTGGGGACATACGTAGCTGTTTTCATAGCTGGACTACAAGCAACAACAA 
3-2-1-8      CATTCTTTCTGTTACGCATTCGGTGAGCTGTTTTCATAGCTGGACTACAAGCAACAACAA 
                    * *  *  * *       *********************************** 
 
luc          AGCATTCTGGATTCCCTGTGAGGATGGATAATGCTGTACCGATTGTACCCCAGGCACCAG 
3-2-1-8      AGCATTCTGGATTCCCTGTGAGGATGGATAATGCTGTACCGATTCACCCCCGGTTCTCCC 
             ********************************************   **** *    *   
 
luc          CTGCTCAGCCACTACAGATTCAGTCAGGAGTTCTCACGCAGGTAAAAGCTAGAGCAATGT 
3-2-1-8      CG--------CCTGCATATTCTCTCGAGATGTCTATCCTGTGTATTATCTAGCACTATGG 
             *          ** ** ****  **  **  ***  *    ***  * ****  * ***  
 
luc          GGATACTCAGTATTGCTAAACACTATTGAGATTCAGATATTTTGTCCTAGAAAATGGTAT 
3-2-1-8      AGATACACATATTTGGTCATAACTAATGATATTCACATATTGTGTCAGAAAAAGGGGGAT 
              ***** **   *** * *  **** *** ***** ***** ****  * ***  ** ** 
 
luc          TTCCTTTGACTATAAGATCTTTCTTGGTCATGATTCAGTGGACTTAAAATGAAACATCTC 
3-2-1-8      TTTTTTTGACTGGATCTTTTTTGT-GCATCTGATTGGAAAAATATAAAAAGAAATCTCTC 
             **  *******  *   * *** * *    *****      *  ***** ****  **** 
 
luc          TATGGAACAATATACTAATTCCTAACACTATTGCAACTCTGCCATTGTCTTCCTTAGACT 
3-2-1-8      TATAGAACAATACAATAACTCTTAACTATTGCGCCTCTCTCCCTGTGTCCTCACTATATT 
             *** ******** * *** ** ****  *   **  **** **  **** **  ** * * 
 
luc          TGCAGGGAAAAAATATCCAGACATTCTTGAGAAATGGTCTTCTGAGTAAGTTTACTCTAA 
3-2-1-8      GGCGGAAAAAAAATCCCCACACTCTCCTGAAAATTGCTCCTCAGAGTCGGTACACTCTTT 
              ** *  *******  *** **  ** *** ** ** ** ** ****  **  *****   
 
luc          TTTTGCGGGGTGAAGCGAATA 
3-2-1-8      TTGTGGGGGGAGGAGCGAA-- 





Supplemental Figure S 3-5: Growth study of the Luc-HEK-HIPK1 KO cells 
A) Viable cell density, B) Viability, C) Glucose and D) Lactate as a function of time (days) for 






Supplemental Table S 3-1: Information for PCR primers 
 









Luc-HEK-mir-22 *  * 
Luc-HEK-mir-22-pool    









Luc-HEK-HIPK-KO **   




microRNA Prod Cat No
RNU
Hs_RNU6-2_11 miScript Primer 
Assay MS00033740
mature miR-22-3p










HIPK1 ACAGTACTCCCAGACCTTGC CGCTTCACCCCGCTAAAATTA for construct 3
TGAGCCCAGATAGCATCACT GTCCACTGAATCATGACCAAGA
HIPK1 for mutations CGCTTCACCCCGCAAAATTA TGGAGATGGGATGAATATTGTGT
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Chapter 4 Continuous production process of retroviral vector for 
adoptive T- cell therapy 
Abbreviations: ATF, alternating tangential flow; CAR, chimeric antigen receptor; DMEM10, 
Dulbecco’s Modified Eagle Medium supplemented with 10% Fetal Bovine Serum Penicillin-
Streptomycin and 6mM final concentration glutamine; ELISA, enzyme-linked immunosorbent 
assay; IFN-γ, interferon gamma; PBL, Peripheral blood lymphocytes; PBS, Phosphate Buffered 
Saline; TCR, T-cell receptor; TU, transducing units;  
4.1 Summary  
Adoptive T-Cell therapy is being considered as a promising method for cancer treatment. PG13 
cells, anchorage-dependent derivatives of NIH3T3 mouse fibroblasts, are being used to stably 
produce retroviral vectors that transduce the T-cells. This chapter describes an effort to scale up 
viral vector production, in which PG13 cells were propagated on microcarriers in a stirred tank 
bioreactor utilizing an alternating tangential flow perfusion system. Microcarriers are 10 µm – 0.5 
mm beads that support the attachment of cells and are suspended in the bioreactor that provides 
controlled growth conditions. As a result, growth parameters, such as dissolved oxygen 
concentration, pH, and nutrients are monitored and continuously controlled. There were no 
detrimental effects on the specific viral vector titer or on the efficacy of the vector in transducing 
the T-cells of several patients. Viral vector titer increased throughout the 11 days perfusion 
period, a total of 4.8 x 1011 transducing units (TU) were obtained with an average titer of 4.4 x 
107 TU/mL and average specific productivity of 10.3 TU per cell, suggesting that this method can 
be an efficient way to produce large quantities of active vector suitable for clinical use. 
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4.2 Introduction  
Adoptive T-cell Therapy is a rapidly growing field that uses the patient’s immune system to battle 
cancer cells [154]. The patient’s own T-cells are modified by genetic engineering to enhance their 
interaction with the cancer cells and improve their capability to attack them [155]. One of the 
approaches for T-cell modification is to add tumor-specific T-cell receptors (TCR) or chimeric 
antigen receptors (CAR) to the patient T-cells by transducing cells collected from the patient with 
the retroviral vector [156]. Following the transduction, the modified cells are administered back 
to the patient [157]. 
Retroviral vector can be produced in the PG13 packaging cell line derived from NIH3T3 mouse 
cells stably expressing the Moloney murine leukemia virus gag-pol proteins and the Gibbon ape 
leukemia virus envelope protein [158]. These cells are stably transfected with gammaretroviral 
backbone encoding TCR or CAR for constitutive production of secreted retroviral vector. In 
1994, von Kalle et al. published an article describing the use of PG13-derived retroviral vector for 
the transduction of CD34+ cell [159] and in 1995, Bunnell et al. described the use of PG13-
derived retroviral vector for transduction of human peripheral blood lymphocytes [160]. Then in 
1997, Bunnell et al. used PG13-derived vector to assess persistence of gene-marked cells in non-
human primate model [161]. In 2005, Cornetta et al. published the National Gene Vector 
Laboratory’s (Indiana University) collective PG13 vector production experience [162], and the 
first clinical data reported was in 2006 by Morgan et al [163]. Since 2006, many groups have 
published numerous clinical results describing the introduction of T-cell receptors and chimeric 
antigen receptors using PG13-derived vector products [164, 165]. The PG13 cells are anchorage-
dependent cells traditionally propagated in dishes, T flasks, roller bottles and cell factories [158, 
166] where the media can be harvested several times in a batch mode for viral vector production. 
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Recently, these cells have been propagated in a packed-bed bioreactor which allows continuous 
media replacement and vector harvest increasing production efficiency [167].  
A promising alternative production approach is the use of microcarriers support for growing 
anchorage-dependent PG13 cells. Microcarriers, first described in the 1960s by van Wezel [168], 
are small, approximately 10 µm – 0.5 mm, charged, coated or porous beads that provide a surface 
for anchorage dependent cells suspended in a culture medium, have been utilized effectively for 
propagation of anchorage-dependent cells in bioreactors for production of different biologicals 
[169]. There has been a significant amount of work associated with improving capabilities of cell 
culture using microcarriers [170, 171]. Microcarriers have been utilized for cells and virus 
production for vaccines such as polio virus, as well as for antibodies and recombinant proteins 
[172]. Recently, attention has been directed towards using microcarriers for growth and 
expansion of mesenchymal and pluripotent stem cells [173, 174]. 
Microcarriers provide support for anchorage-dependent cell growth in the bioreactor and, 
therefore, like other anchorage-dependent cell methodologies, the surface area is finite, e.g.3 g/L 
of Cytodex 1 provide a surface area of 13.2 cm2/mL. However, since microcarriers are kept in 
suspension, it is possible to replace the media while maintaining the cells in the bioreactor 
without disrupting their growth, practically simulating suspension culture conditions, and, 
therefore, extending the production period [175].  
This chapter proposes a procedure for continuous large-scale production of retroviral vector by 




4.3 Materials and Methods  
4.3.1 PG13 Cells 
A PG13 stable packaging clone was previously generated, constitutively expressing a gamma 
retroviral vector containing a T-cell receptor using the PG13 gibbon ape leukemia virus 
packaging cell line (ATCC CRL-10686) and the human ecotropic packaging cell line Phoenix 
ECO (kindly provided by Dr. Gary Nolan, Stanford University, Stanford, CA) as previously 
described [166]. Cells were maintained in tissue culture flasks in a humidified incubator set at 5% 
CO2 and 37°C. The PG13 cells were grown in Dulbecco’s Modified Eagle Medium (Gibco, 
Gaithersburg, MD) supplemented with 10% Fetal Bovine Serum (Atlanta Biologicals, Flowery 
Branch, GA), Penicillin-Streptomycin (Gibco) and 6 mM final concentration glutamine (Gibco) 
abbreviated as DMEM10, both in the tissue culture flasks and the bioreactor.  
4.3.2 Microcarriers 
Cytodex 1 microcarriers (GE Healthcare Life Sciences, Marlborough, MA) were used at a 
concentration of 3 g/L of culture plus 10% to account for transfer losses. The microcarriers were 
rehydrated in 75 mL/g Phosphate Buffered Saline (PBS, Lonza, Rockland, ME) for at least 3 
hours at room temperature in a siliconized glass bottle while being agitated on a rocking platform. 
The microcarriers were allowed to settle and the PBS removed. The microcarriers were then 
washed with 40 mL/g of PBS and resuspended in 40 mL/g PBS for autoclaving, with the 
bioreactor. After autoclaving, 30 mL/g of DMEM10 was used to wash the microcarriers. The 
microcarriers were then transferred to the bioreactor with some of the initial 500 mL DMEM10 




A one liter working volume univesel bioreactor with marine blades (Sartorius, Goettingen, 
Germany) equipped with 16 cm dissolved oxygen (Hamilton, Reno, NV) and pH (Hamilton) 
electrodes, configured as shown in Figure 4-1, was connected to a DCU touch controller 
(Sartorius). The growth was initiated at 37°C, pH 7.5 and air flow of 0.3 L/min with 3.3 g of 
Cytodex 1 microcarriers, in 500 mL of DMEM10 and approximately 1.7x108 cells. For the first 4 
hours, the agitation was set at 100 rpm for 2 min followed by 5 rpm for 20 min to allow for cell 
attachment. After 4 hours, the agitation was set at 100 rpm and an additional 500 mL of 
DMEM10 was added. Dissolved oxygen, pH and temperature were continuously monitored and 
controlled (see next paragraph). Daily samples were collected for measurements of cell count 
nutrients, metabolite levels, and pH (Figure 4-1).  
Agitation and airflow increased as the dissolved oxygen decreased, and oxygen was added by 
cascade control at 1 L/min when the dissolved oxygen concentration reached 50%. Agitation was 
also increased to 110 rpm when the microcarriers started settling. When the glucose level reached 
2 g/L and/or lactate increased to 2 g/L, the media was harvested and fresh DMEM10 was added. 
The harvest medium was used to measure viral vector titer as described in the next section.  
4.3.4 Perfusion 
An alternating tangential flow (ATF) unit (Repligen, Waltham, MA) specific for microcarriers 
culture (ATF2 MC) equipped with microcarrier screen filter module (73 µm pore, 162 cm2) 
operated by C24 controller was set up as shown in Figure 4-1. On day two, the ATF was turned 
on with pressure setting of 0.9 units, and exhaust setting of 0.3 units to prime the system for 
perfusion. The bioreactor was run as batch culture until day four when the feed and harvest 
pumps were turned on. The feed and harvest flow rates were set at 0.69 mL/min for a total 
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bioreactor volume change in 24 hours. The harvest was collected at 24-hour intervals for 
measurements and samples were kept in the -80°C freezer until further use. 
4.3.5 Cell count and viability measurements 
Samples were collected as described in section 4.3.3. To measure the cell count and viability from 
the microcarriers, 1 mL of culture with microcarriers was allowed to settle in a 1.5 mL Eppendorf 
tube. The supernatant was removed and strained into a cell strainer tube. The microcarriers were 
washed with 1mL of PBS which was removed and strained in to the tube and 1 mL of Trypsin-
EDTA (Gibco) was added to the cells. After a 7-min incubation at 37°C, this was then also 
strained into the mixture with media and PBS of which 300 µL was counted using the trypan blue 
exclusion method with the Cedex HiRes cell counter (Roche, Indianapolis, IN). 
4.3.6 Nutrient and metabolite measurements 
Daily samples were measured for nutrient and metabolite concentrations. Glucose and lactate 
concentrations were measured using a YSI 2700 biochemistry analyzer (Yellow Springs 
Instrument Co., Yellow Springs, OH). Osmolality was measured with a Vapro vapor pressure 
osmometer (Wescor, Logan, UT). Glutamine, glutamate, and ammonia concentrations were 
measured using the Cedex bioanalyzer (Roche). These measurements were made in accordance 
with the manufacturer’s instructions. 
4.3.7 Viral Vector Titer and cytokine release assay 
Viral vector titer was determined by transducing 2x106 cells/mL Peripheral Blood Lymphocytes 
(PBLs) from each of three patients, with the supernatant from the perfusion culture at dilutions of 
1:1, 1:9 and 1:99. The three dilutions results and the three patients were averaged together to 
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determine an overall viral titer. PBLs were stimulated with 300 IU/mL interleukin 2 (Prometheus 
Laboratories, San Diego, CA) and 50 ng/mL OKT3 (Miltenyi Biotec, Auburn, CA) on day 
zero. A 24-well non-tissue culture treated plate was coated with 10 µg/mL (0.5mL/well) 
retronectin (Takara Bio, Shiga, Japan) on day one and stored overnight at 4°C. After blocking 
with 5% Human Serum Albumin, (HSA, Valley Biomedical, Winchester, VA), serially diluted 
supernatants were added (1mL/well) on day two, centrifuged for 2h at 2,000 x g, followed by the 
addition of PBL, 0.25x106/mL. The cells were then centrifuged for 10 min at 1,000 x g and 
incubated at 37°C and 5% CO2. On day eight, the T-cells were analyzed by FACS using 
fluorescein isothiocyanate- or phycoerythrin- conjugated antibodies directed against CD3 or CD8 
(BD Biosciences, San Jose, CA) and FITC-conjugated MART-127-35)/HLA-A*02 tetramers 
(Beckman-Coulter, Brea, CA). The relative fluorescence of live cells was assessed using the 
FACSCanto flow cytometer (BD Biosciences) and data analysis using the Flowjo software 
(Flowjo LLC., Ashland, OR). The viral vector titer was calculated as (Total cells)(% 
TCR+)(Dilution Factor)/supernatant volume. 
Two groups of melanoma cell lines, each with two cell lines, mel526 and mel624 (HLA-
A2+/MART-1+) and mel888 and mel938 (HLA-A2−) were isolated from surgically resected 
metastases as previously described [176] and were cultured in R10 medium consisting of RPMI 
1640 medium (Gibco) containing 10% fetal bovine serum. Functional assessment of TCR-
transduced PBLs was carried out by co-culture of 105 transduced T-cells with 105 tumor target 
cells from each of four melanoma cell lines and incubated in 200 µL for 18 hours at 37°C as 
previously described [166]. After the co-culture, specific recognition of tumor targets was 




4.4 Results  
4.4.1 Cell growth on microcarriers in a perfused bioreactor 
To determine if continuous perfusion mode is a feasible alternative production method for 
retroviral vector from PG13 cells a one-liter bioreactor, equipped with an alternating tangential 
filtration device specifically designed for microcarrier culture, was set up. After the initial 
seeding and growth period, the bioreactor was operated continuously for 10 days in a perfusion 
mode replacing one volume per day; the growth parameters are summarized in Figure 4-2A and 
B. As was expected from this growth strategy, cell concentration increased from 1.7 x 105 
cells/mL to approximately 1-3 x 106 cells/mL, a 6- to 17-fold expansion. As the culture grew, it 
became difficult to obtain accurate viable cell density values due to cell aggregation, both on the 
microcarriers (Supplemental Figure S 4-1) and accumulation in the filtration device. However, 
the metabolite profile indicated that the cells continued to grow uninterruptedly (Figure 4-2B). 
Glucose and glutamine were maintained around 2 g/L and 2 mmol/L respectively, and lactate, 
glutamate and ammonia were maintained at around 2 g/L, 1 mmol/L, and 3 mmol/L respectively. 
The osmolarity was kept constant at about 330 mmol/kg when the bioreactor was in perfusion 
mode. In addition, cell viability improved from approximately 80% initially to 95% following the 
medium perfusion process (Figure 4-2 A).  
4.4.2 Vector production  
Viral vector titer increased throughout the perfusion period (Figure 4-3 A) with an average 
specific productivity of 10.3 transducing units (TU) per cell. Collecting one bioreactor volume 
per 24 hours (one liter) in the perfusion phase, a total of 4.8 x 1011 TU was obtained in 11 liters of 
harvest media with an average titer of 4.4 x 107 TU/mL (Figure 4-3 A). Vector titer was 
calculated by measuring the transduction efficiency of the T-cells with the retroviral vector 
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harvested from the bioreactor for each of three patients at three different dilutions. Representative 
titration data from a single patient and dilution is shown (Figure 4-3 B). Complete information 
from the 3 patients can be found in Supplemental Figure S 4-3. 
To evaluate the quality of the viral vector produced, a cytokine release assay was performed to 
determine how well the transduced T-cells recognize HLA-matched antigen-positive tumor cells. 
Representative data from a single patient in Figure 4-4 shows that the transduced T-cells 
specifically recognize HLA-A2+/MART-1+ cell lines (526 and 624) and not the HLA-A2- lines 
(888 and 938) as measured by IFN-γ ELISA. Complete information for the 3 patients can be 
found in Supplemental Figure S 4-4. 
4.5 Discussion  
Viral-mediated gene delivery is an efficient way to genetically modify human lymphocytes and 
other cells. Therefore, for cases where a single vector product can be used to engineer cells for 
many patients, production of an appropriate amount of retroviral vector from PG13 cells is 
essential for successful cell therapy studies. PG13 are anchorage-dependent cells and, therefore, 
the conventional stirred tank bioreactor, commonly used for large scale production of suspension 
mammalian cells, is not a workable method. As a result, the existing production methods for viral 
vector from PG13 cells are based on utilizing cell factories, roller bottles and fixed bed 
bioreactors [166, 167, 177]. In this report we described a retroviral production process from PG13 
cells propagating on microcarriers in a stirred tank bioreactor by utilizing continuous media 
replacement using perfusion. In the described process, the cells were kept in the bioreactor for a 
period of 15 days in a stable physiological environment, which was confirmed by stable 
concentration of metabolites and nutrients, and by the viral vector production titer. In the 
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perfusion period, eleven liters were continuously collected from one-liter bioreactor, 4.8x1011 
transducing units were collected representing average specific productivity of 10.3 TU per cell.  
The PG13 cells attached to the microcarriers were found to be well-matched to the growth 
conditions in the bioreactor. Once attached to the microcarriers, they continued to grow to 
confluency while maintaining stable viral titer. However, microscopic observation showed that 
the cells grew in several layers on the microcarriers and when the system was inspected at the end 
of the production, some of the cells were found to accumulate in the retention device. Potentially 
these accumulations can affect the viral vector production efficiency and the cells growth 
parameters, but practically no adverse effect was observed; not on the vector production 
capability and not on the metabolic activity of the cells as was evaluated by the metabolite 
concentrations throughout the two weeks production process. Very likely the reason for this 
behavior is that the culture is well mixed and aerated allows accumulations of loosely packed 
cells to form. Future studies should therefore include optimization of the microcarriers 
concentration, cell seeding density and perfusion rate. 
The filtration assembly has a retention volume of approximately 350 mL and stroke volume of 
approximately 100 mL; when the system operates, about half of the one-liter bioreactor is 
contained in the filtration unit, these conditions were found to be appropriate for maintaining the 
growth and the vector production. Based on the performance of the tested filtration assembly we 
predict that the same size filtration unit will likely be suitable for perfusing larger volumes, 
perhaps up to 5 liters and would possibly provide more homogenous culture, but this needs to be 
evaluated in additional experiments. An unexpected advantage of using the retention assembly is 
the increased dissolved oxygen supply to the microcarrier culture of the PG13 cells, resulting 
from charging and discharging the culture into the retention assembly. Sparging air and oxygen 
directly into the microcarrier culture was found to cause aggregation of the PG13 cells around the 
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air sparger, but surface aeration with or without oxygen, together with the tangential mixing by 
the retention device and the vertical mixing of the bioreactor, kept the dissolved oxygen above 
50% air saturation throughout the process without difficulties as seen in Supplemental Figure S 
4-2. The process lasted 15 days but certainly could go longer, continuously producing more viral 
vector. 
Compared with existing production strategies such as stationary processes done in T flasks and 
roller bottles that although robust, are labor intensive and require a large footprint [178, 179], the 
described process offers several advantages. Fixed-bed bioreactor [180] is another possible 
production approach that eliminates some of the hurdles of the stationary process; it requires 
smaller surface area and can maintain the growth parameters such as pH and DO, however, it has 
imperfect mixing so there is limited nutrient distribution and the cells do not have equal access to 
nutrients. We believe that the continuous process described in this work, that uses microcarriers 
to create suspension like perfusion culture, by utilizing alternating tangential filtration device, is 
an efficient way to produce the large quantities of active vector needed for clinical use. The next 
chapter proposes a cell engineering method, again using non-coding RNA, to improve retroviral 
titer for the adoptive T-cell therapy. 
Contributions from Collaborators: 
Dr. Steven Feldman contributed to experimental design, drafting, and revising this manuscript 
and members of his laboratory performed the measurement of the vector titration and IFN activity 
assay.   
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Figures and Tables 
Figure 4-1: Bioreactor setup  
Drawing (not to scale) of the perfusion bioreactor layout with the ATF filtration system adapted 
from Bleckwen et al. [181]. The pump flow rates are controlled individually, the ATF has a 









Figure 4-2: Culture performance 
A) Cell growth and perfused volume. The viable cell density (diamonds), viability (circles) and 
total perfused volume (solid line) as a function of process time. B) Nutrients and Metabolite 
Concentrations. Glutamate (solid circles), glutamine (open circles), ammonia (solid triangles), 
osmolarity (open diamonds), glucose (solid squares) and lactate (open squares) concentrations as 
a function of process time. The arrow shows the day perfusion was initiated. 
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Figure 4-3: Vector production  
A) Vector titer (closed circles) and total accumulated vector (solid line) as a function perfusion 
time. Vector concentration is an average of three dilutions for each of three patients. B) 
Fluorescence Activated Cell Sorting Analysis (FACS) Data after perfusion was initiated from one 
of the three patients and 1:9 dilution shown. (Because the murinized MART-1 TCR expresses the 




Figure 4-4: Vector activity by functional analysis of TCR-transduced PBL 
A representative assay showing the IFNγ release following overnight co-culture with HLA-
A2+/MART-1+ tumor targets (526, 624) and the antigen-negative, HLA mismatched controls 
(888, 938) for samples after perfusion was initiated. As expected, cells released no IFNγ against 




Supplemental Figure S 4-1: Microscopic images of PG13 cells on microcarriers  
A. Day 2 one day after seeding, B. Day 7 at confluence, C. Day 8 beginning to layer, and D. Day 






Supplemental Figure S 4-2: Complete Fluorescence Activated Cell Sorting Analysis (FACS).  
Data from other dilutions and patients after perfusion was initiated. (Because the murinized 













Supplemental Figure S 4-3: Complete vector activity by functional analysis of TCR-transduced 
PBL  
Assay showing IFN release following overnight co-culture with HLA-A2+/MART-1+ tumor 
targets (526, 624) for samples after perfusion was initiated. Cells released no IFNγ against 







Supplemental Figure S 4-4: Bioreactor parameters  
Air (blue), carbon dioxide (green), oxygen (teal), pH (red), dissolved oxygen (purple), agitation 




Chapter 5 Method development for a high throughput RNAi screen 
for improving retroviral vector titer 
Abbreviations: CAR, Chimeric Antigen Receptor; DMEM10, Dulbeccoo’s Modified Essential 
Media containing 10% Fetal bovine serum, penicillin, streptomycin, and glutamine; Env, 
Envelope; Gag, Group Specific Antigen; GFP, Green Fluorescence Protein; miRNA and mir, 
microRNA; Pol, Polymerase; RNAi, RNAinterference; siNC, negative control siRNA; siPLK1, 
positive control siRNA; siRNA, small interfering RNA; TCR, T- cell receptor;  
5.1 Summary  
Gammaretroviral vector for Adoptive T-cell therapy can also be transiently produced by 
transfecting HEK 293 GP cells constitutively expressing Gag-Pol with an envelope plasmid and 
an expression vector plasmid. Increasing the efficiency of production of the retroviral vector is 
essential for scale up and scaling out as Adoptive T-cell therapy progresses. As discussed in 
Chapter 1, the expression of various recombinant proteins, secreted proteins, membrane proteins, 
antibodies, and recombinant adeno-associated virus viral vectors, have been found to improve 
following addition or deletion of small non-coding RNA such as microRNA and siRNA. High 
throughput RNAi screens for microRNA or siRNA make identifying the effect of individual 
small RNA more efficient. This chapter describes the steps taken to design a high throughput 
RNAi screening of HEK 293 GP cells for determining if addition or deletions of specific 




5.2 Introduction  
As discussed in chapter four, adoptive T-Cell Therapy is a cancer treatment approach in which 
tumor specific T-cells are isolated from the tumor or created by modifying T-cells, are expanded 
and returned to the patient with the ability to fight tumor cells [182]. The T-cells recognize 
antigens specific to the tumor via the antigen receptor [155]. Modifications to the T-cells for 
adoptive T-cell therapy can include adding specific T-cell receptors (TCR) or chimeric antigen 
receptors (CAR) with retroviral vectors, lentiviral vectors, or other methods [183].  
Retroviral vectors have been used for gene and cell therapy since the first clinical trial in 1990 
[184]. A commonly used γ-retroviral vector uses the Moloney Murine Leukemia Virus as a 
backbone [185]. The main components of the retroviral vector are the group specific antigen 
(Gag)- Polymerase (Pol), the envelope (env) and the viral genome containing the transgene [186]. 
As γ-retroviral vectors have developed, for safety purposes, these components have been split up 
into separate constructs so the third generation of vector contains a two-plasmid packaging 
system [187, 188]. One process used to produce the viral vector is by transfecting HEK 293 GP 
cells that constitutively express the Moloney murine leukemia virus Gag-Pol with an endogenous 
feline virus (RD114) envelope plasmid and TCR or CAR vector plasmid [189-191]. This method 
transiently produces a γ-retroviral vector that can then be used to transduce patient T-cells.  
Increasing efficiency of the production of the retroviral vector is essential for scale up as 
Adoptive T-cell therapy progresses. In the previous chapter, extrinsic methods using a continuous 
microcarrier perfusion bioreactor were employed to improve retroviral vector production. In this 
chapter, cellular engineering is employed, returning to the non-coding RNA of chapters one 
through three.  
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As discussed in chapter one, the expression of various recombinant proteins, secreted proteins, 
membrane proteins, antibodies, and recombinant adeno-associated virus viral vectors, have been 
found to improve following addition or deletion of small non-coding RNA [1]. RNAinterference 
(RNAi) molecules such as microRNA (miRNA or mir) and small interfering RNA (siRNA) have 
been of particular interest because of their simplicity and ability to improve recombinant protein 
production without additional translational burden [46]. High throughput RNAi screens for 
microRNA or siRNA make identifying effect of individual small RNA more efficient [192]. A 
previous high-throughput microRNA screen [43] and siRNA screen [73] have demonstrated the 
ability to use these high-throughput screens for improving recombinant protein expression.  
This chapter describes the steps taken to design a high throughput RNAi screening of HEK 293 
GP cells for determining if additions or deletions of specific microRNA or siRNA will improve 
the retroviral vector titer. Using high-throughput double transfection, first by microRNA and then 
by the retroviral vector, the cells will be screened for green fluorescence as an indicator of vector 
titer. The screen design includes adapting and miniaturization of the transfections and 
optimization in the 384-well plate. This design has the potential to be expanded to other types of 
viral vectors such as lentiviral vectors. 
5.3 Materials and Methods  
5.3.1 Cell line and plasmids 
293GP retroviral packaging cell line consisting of an HEK293 phoenix cell line constitutively 
expressing the Moloney murine leukemia virus (MMLV) gag and pol components was kindly 
provided by Dr. Feldman (NCI, NIH, Bethesda, MD) along with an endogenous feline virus, 
RD114, envelope plasmid and pMSGV1-GFP vector plasmid. An RD114 envelope plasmid 
containing Green Fluorescent Protein (RD114-GFP) was created by Medigen (Fredrick, MD, 
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Supplemental Figure S 5-1). Cells were maintained in Dulbeccoo’s Modified Essential Media 
(DMEM) (Gibco, Gaithersburg, MD) containing 10% Fetal Bovine Serum (FBS) (Gibco), 
penicillin/streptomycin (Gibco), and glutamine (Gibco) (DMEM10) at 37˚C with 5% CO2 in a 
humidified incubator. The 293GP cells are very fragile and quickly produce an acidic 
environment more rapidly than standard HEK293s. Growing them too dense, is not good for them 
and they often slough off the flask prior to confluency.  
5.3.2 microRNA reverse transfections 
Plates are spotted with 20 nM final concentration of microRNA (or siRNA) including a non-
targeting control, Ambion Silencer Select Negative Control (siNC), (Thermo Fisher Scientific, 
Waltham, MA) and a positive control, (siPLK1), (Thermo Fisher Scientific). Lipid reagent is 
added to serum free DMEM and then added to the wells. While the plate is incubating for a 
maximum of 30 minutes, the cells are prepared in DMEM containing 20% FBS which are then 
added to the wells and the plate is incubated at 37˚C. 
5.3.3 Viral vector forward transfection 
After incubating the microRNA transfection for 48 hours, the retroviral vector transfection is 
performed in a forward transfection. Lipid reagent is added to OptiMEM (Gibco). In a separate 
tube the expression vector plasmid and the RD114 plasmid are added to OptiMEM. These are 
incubated separately for 5 minutes, combined and then incubated for 20 minutes after which the 




5.3.4 96-well feasibility study 
To test the process in 96-well plates, the siNC and siPLK1 were used on day 1 with multiple 
RNAiMAX (Thermo Fischer Scientific) concentrations (the 96-well equivalent of the 384 well 
plate 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08 µl per well) and two different cell 
concentrations (7,500 and 10,000 cells per well). The cells were then transfected with 
lipofectamine 2000 (Thermo Fisher Scientific) and the viral vector plasmids. The Green 
Fluorescent Protein (GFP) production was visualized with a Leica fluorescent microscope (Leica 
Biosystems, Buffalo Grove, IL) and measured on the SpectraMAX microplate reader (Molecular 
Devices, San Jose, CA). The cell viability was measured with the CellTiter-GLO assay (Promega, 
Madison, WI) and measured on the SpectraMAX.  
5.3.5 Vector production verification 
In addition to observing GFP in the 293GP cells, a rapid method to evaluate the presence of 
retroviral vector was to use the vector to transduce 293 cells and observe if the cells acquired 
fluorescence. Supernatant was collected from the transfected 293GP cells, centrifuged and 
filtered. This was then used at a 1:1 dilution with fresh media to transduce 293 cells plated 24 
hours prior. Between 24 hours and 96 hours after incubation, cells were observed for changes in 
phenotype including GFP and growth. Media was changed 24 hours after transduction. The 
transduction was not optimized due to its use as a quick method of checking if viral vector was in 
the supernatant. For a viral vector titration, T-cells will be transduced according to a tested and 




5.3.6 Assay Development 
5.3.6.a Cell concentration optimization  
Cell number optimization was performed by plating three columns each in 384 well plate at 500, 
750, 1000, 1500 and 2000 cells per well in 40 µL DMEM10. After 96 hours, the plate was fixed, 
stained, and imaged with the ImageXpress (Molecular Devicess). 
5.3.6.b Fixing, Staining, and Imaging 
To optimize the fixing and staining method various concentrations of paraformaldehyde (Electron 
Microscopy Sciences, Hatfield, PA) and Hoechst 33342 (Thermo Fisher Scientific) stain were 
tested with and without Phosphate Buffered Saline (PBS) washes. The optimal process was for 
cells to be fixed and stained simultaneously using a mix of 16% paraformaldehyde, 2000x 
Hoechst 33342 stain in PBS. 20 µL of this mixture was layered on top of the 60 µl of media in the 
wells, incubated for 30 min with no washes and read with the ImageXpress for nuclear cell count 
and GFP.  
5.3.6.c microRNA transfection optimization 
Lipid concentration was optimized using 0.01, 0.02, 0.03, 0.04 and 0.05 µL of RNAiMAX with 
siNC and siPLK1. After 96 hours, the plate was fixed, stained, and imaged with the ImageXpress. 
Lipid type for the microRNA transfection was optimized using 0.03 and 0.05 µL of RNAiMAX, 
Dharmafect1 (Dharmacon, Lafayette, CO) and Dharmafect4 (Dharmacon) with siNC and 
siPLK1. After 96 hours, the plate was fixed, stained, and imaged with the ImageXpress.  
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5.3.6.d Viral vector transfection optimization 
The vector optimization was performed after the microRNA optimization and 48 hours after 
either a microRNA transfection of siNC and siPLK1 or plating cells. Initially, it was assumed, 
that the viral vector transfection should work with the scaled quantities using a total of 20 µL of 
OptiMEM so the lipid quantity was kept at 0.03 µL per well and the expression vector and 
RD114 were transfected at a 2:1 ratio of differing amounts to determine the optimum quantities, 
however, the volume effect had not been considered and the transfection was not effective; there 
was no GFP signal. After taking volume change into account, the transfection was scaled by 
volume and 0.15 µL of lipid was added with 30 ng of expression vector and 15 ng of RD114 to 
achieve a GFP signal. Then optimization could begin.  
Different types of lipid were tested including Lipofectamine 2000, Dharmafect4 and DNAin 
(MTI-Global Stem, Gaithersburg, MD). 48 hours after the vector transfection, the plate was fixed, 
stained, and imaged with the ImageXpress.  
Once the lipid was selected, the quantity of lipid, expression vector and RD114 were varied with 
the same ratios to each other in an attempt to improve transfection efficiency. After achieving a 
decent GFP signal, the RD114 was removed from the transfection in order to optimize the GFP 
signal, using a constant DNAin concentration of 0.15 µl per well and varying amounts of 
expression vector from 10-120 ng/well.  
5.3.7 PCR for RD114 transfection 
Since RD114 does not have a visible marker, PCR can be performed to detect the presence of the 
RD114 after detection. Primers were designed against the RD114 envelope: forward - 
tagctggactgggaatcacc and reverse – cctccttgttctgccgttag.  
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5.4 Results 
5.4.1 Adapt and Miniaturize the transfection procedure 
The conditions for the retroviral vector production provided are not suitable for a high throughput 
screening. The initial viral vector transfection procedure for the retroviral vector production was 
given for 10 mm poly-lysine coated plates. Cells were plated 24 hours prior to the transfection 
with a media change both prior to the transfection and the day after the transfection, performing 
the transfections with lower volumes than routine growth.  
It was necessary to scale the original vector transfection protocol to a smaller plate in order to test 
feasibility of the double transfection process, . Additionally, it was necessary to eliminate the 
extra media changes for high throughput practicality. Initially the transfection was scaled to a 24-
well plate, then to a 96 well plate and finally the 384-well plate (Table 5-1). This scale was done 
by surface area. To determine that the transfection was effective at the 24-well and 96-well scale, 
fluorescence was detected with a Leica fluorescent microscope. For fluorescence detection and 
practicality, tissue culture treated, black, clear bottom plates were used instead of poly-lysine 
coated plates for the 96-well and 384-well plates.  
While the tropism for RD114 envelope protein is best for hemopoietic cells, the supernatant was 
tested on 293 cells as well and was effective at transducing some of them, as identified by their 
fluorescence, which verified retroviral vector product. Cell plating concentrations were adjusted 
in the 384-well format as described in section 5.4.4. 
When the procedure was finally miniaturized to the 384-well scale, it became clear that scaling by 
volume instead of surface area was more effective, especially since the smaller volume was 
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impractical and it was necessary to increase both the initial volume, since the first media change 
was not performed, and the additional volume.  
5.4.2 Testing the RD114-GFP plasmid.  
The idea of adding GFP to the envelope protein, RD114, was that the GFP could be observed in 
the retroviral vector particles [193]. However, since the GFP is part of the plasmid, it is 
transcribed and translated by the SFFV promoter that produces the RD114 envelope protein. The 
GFP is expressed inside the cells as the plasmid is processed and not just in the retroviral vector 
particles. Therefore, it was decided to use the GFP expression vector that also expresses GFP in 
the cells and the RD114 envelope without GFP assuming the GFP in the envelope might have a 
negative effect on the packaging of the vector. It’s assumed that the amount of GFP 
approximately correlates with the amount of plasmid being translated into the viral vectors and 
therefore approximately correlates with the viral vector titer, however this needs to be confirmed 
with the validation experiments and viral vector titration from cells that display different amounts 
of GFP after a completed screen. 
5.4.3 Feasibility of the two-transfection process 
The plan for transfecting the 293GP cells with microRNA and then with the retroviral vector 
plasmids was designed for a five-day process as shown in Figure 5-1. On day 1, a reverse 
transfection is performed whereby the microRNA is added to the plate followed by the lipid 
reagent and finally the cells. On day 3 (48 hours later) the viral vector forward transfection is 
performed where the lipid, RD114 envelope plasmid and expression vector plasmid are 
complexed and then added to the cells. On day 5 (48 hours after the vector transfection and 96 
hours after the microRNA transfection) the cells are measured (Figure 5-2). 96-well plate 
experiments were used to demonstrate the feasibility of the double transfection (Figure 5-3). 
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While the GFP did not measure significantly higher in the plate reader, it was higher and GFP 
was seen in the microscope. Since the cell death killed a significant number of cells compared to 
the control and non-transfected cells, there was indication that the double transfection was 
feasible and could be continued at a 384-well scale.  
5.4.4 Optimizing in 384 well plates 
Since the high-throughput screen is performed in 384-well plates, after testing the feasibility in a 
96-well format, the process was optimized in 384-well plates. This included optimizing the cell 
concentration, the fixing and staining procedure, the lipid type and concentration for each 
transfection and the DNA plasmid concentrations for the viral vector transfection (Figure 5-4).  
5.4.4.a Cell concentration optimization 
The original protocol includes plating cells 24 hours prior to the vector transfection. Since, the 
new protocol will include plating them 48 hours prior to transfection and require a different level 
of confluency for measurement, this cell concentration was not useable. For an accurate count for 
the screen, the goal is to have approximately 80% confluency by the time of measurement (96 
hours after plating). The first test was to plate different cell densities for measurement. The 
optimal cell density was 1,000 cells per well, however throughout the optimization process, this 
had to be adjusted since the transfections influenced the final cell count.  
5.4.4.b. Fixing and Staining 
The original process for fixing and staining includes separate steps for fixing and staining for 30 
min with two aspirations and PBS washes and an aspiration and addition of 20 µl of PBS after 
each. The paraformaldehyde is used at a final concentration of 2% and the Hoechst stain is used 
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at a final a dilution of 6000x with extra washes as needed. Unfortunately, when this protocol was 
followed, the cells lifted from the plate and were unable to be counted. Optimization included 
using various combinations of fixing and staining with and without aspiration and PBS washes as 
well as a plate washer. The optimal process was for cells to be fixed and stained simultaneously 
using a mix of 16% paraformaldehyde, 2000x Hoechst 33342 stain in PBS. 20 µL of this mixture 
was layered on top of the 60 µl of media in the wells, incubated for 30 min with no aspiration or 
washes, then read with the ImageXpress for nuclear cell count and GFP.  
5.4.4.c microRNA transfection 
A general starting point for microRNA or siRNA concentration is 0.2 nM. Since RNAiMAX had 
worked in the 96 well feasibility test, this lipid was used to optimize the lipid concentration in the 
384 well plate. Using varying concentrations with the siRNA for negative control and the siPLK, 
the lipid concentration 0.03 µL per well was found to be effective at killing the positive control 
cells with minimal death of the negative control cells, however there appeared to be some edge 
effects so some plate-wide experiments were tested to determine if they were truly edge effects. 
During this time, the RNAiMAX stopped working to transfect the cells; the siPLK stopped killing 
the cells. Fresh vials of cells were tried resulting in the same problem at which point different 
lipids were studied to see if better results could be obtained with a different lipid.  
RNAiMAX, Dharmafect1 and Dharmafect4 were tested with Dharmafect4 having the most 
success. The same experiments with varying concentrations that had previously been performed 
with RNAiMAX were repeated with Dharmafect4 to obtain the optimal concentration again of 
0.03 µL/well. Now that there was an optimized microRNA transfection, the vector transfection 
could be optimized. 
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5.4.4.d Vector Transfection Optimization 
The plan for the vector transfection was to optimize the lipid concentration then optimize the 
DNA plasmids, assuming the same ratio (1 expression vector: 1/2 RD114). Since the lipid 
reagents are toxic, initially in an attempt to reduce the lipid impact on the cells, the same lipid, 
Dharmafect4 was tried for the vector transfection however no GFP was seen in the cells. The 
experiment was scaled back up to 24 well plates with both lipofectamine 2000 and Dharmafect4. 
Dharmafect4 still did not have much GFP, as it turns out Dharmafect 4 is optimized for RNAi 
transfection not plasmid transfection. So, a lipid type optimization step was added using 
lipofectamine2000, Dharmafect 4 and DNAin. At the same time, it was realized that since 20 µL 
of final transfection mixture was being added for a practical purpose, a larger amount of lipid and 
DNA needed to be added, so this was also tested, along with adding smaller total amounts of all 
all the components. DNAin was selected as the best lipid for the vector transfection using 
approximately five times the original concentration, 0.15 µL per well in a total of 20 µL addition. 
Even with the optimal lipid concentration, transfection efficiency was only about 14%. To 
improve this efficiency, the expression vector concentration was individually varied with a 
constant concentration of lipid and no RD114. The optimal concentration was found to be 80 ng 
per well which is a large increase over the 6 ng per well of the scale down conditions used 
initially. 






The work described in this chapter has laid out the foundation for developing a high-throughput 
RNAi screen that can be used to improve retroviral vector titer. The next steps include performing 
a microRNA screen. This will be used to test the function of the screen and identify microRNA 
that can improve the viral titer.  
Candidate microRNAs that increase GFP fluorescence will be identified by analyzing the images. 
Additionally, candidate microRNAs that inhibit cell proliferation or decrease cell viability will be 
identified by counting the numbers of cell nuclei in each well from the images. In this way, with 
one screen, it will be possible to generate two lists of candidate microRNAs, one potentially 
increasing GFP fluorescence and thereby vector production, and the other affecting cell growth or 
viability. Overlaps between these two lists are expected due to the long half-life of GFP and that 
will be taken into consideration when determining hits. Since the GFP in the 293GP cells is 
mostly produced by the plasmid being transcribed, the amount of GFP may not directly correlate 
with vector titer. This needs to be tested with validation transfections and a titration assay, 
transducing T-cells with the vector product. Top performing microRNAs will be selected for 
follow-up with smaller scale verification experiments. After confirmation of viral improvement 
with multiple viral vectors, a stable 293 GP cell line with over expressed or knocked out 
microRNA will be generated. Once these steps are completed and the screen is confirmed usable, 
an siRNA screen can be performed using the same conditions.  
The siRNA screen was not used for proof of concept due to the larger scale of the screen, 3 
siRNAs for each of approximately 22,000 genes instead of one of each approximately 3,000 
microRNAs in the human library, however there are many advantages of using a genome-wide 
siRNA screen. MicroRNAs regulate multiple target genes and therefore when one microRNA is 
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over or under expressed, the effects on the cell are not well known [60, 100]. Targeting a single 
gene with siRNA allows better knowledge of the improvement mechanism and a better idea of 
the effects on the cell. It would also give the opportunity to create a stable knockout cell line as 
seen in chapter three.  
Since the 293GP cells behave differently than HEK293, it would be worthwhile to investigate 
further what happens during the cell cycle. They produce more acid than standard HEK293 cells 
and are very sensitive to changes in the environment. They are not strongly adherent, even less so 
than HEK293 cells so care must be taken not to disrupt them during growth and analysis. Omics 
analyses such as transcriptomics and metabolomics would elucidate some of mechanisms behind 
these differences. 
Because there is room for variation with transfection efficiency even with identical conditions 
and the possibility that the GFP is not exactly representative of titer, it would be helpful to have a 
stably expressing retroviral cell line for the screens so the second transfection (the viral vector 
transfection) is eliminated, reducing some variation. This would make it easier to demonstrate 
that the differences in GFP level are only related to the microRNA differences and more 
indicative of viral titer. 
While there are still clinical trials using γ-retroviral vectors, lentiviral vectors have become more 
popular due to their ability to transduce non-dividing cells and relative safety [194]. Since 
lentiviral vector production is similar to the production of γ-retroviral vectors and stable 
producing cell lines are not common, the process of a two-transfection RNAi screen can likely be 
expanded to lentiviral vectors.  
 
132 
Contributions from Collaborators: 
Dr. Steven Feldman kindly provided the cells and plasmids for use and experimental design. Dr. 
Madhu Lal-Nag was very helpful in experimental design and provided use of her facilities.  
  
133 
Figures and Tables 





Figure 5-2: Images of transfected cells after 96 hours. 





Figure 5-3: Feasibility study in 96-well plate 
The feasibility study in the 96-well plate demonstrates the ability to transfect cells with both 
siRNA and viral vector. A) Cell viability and B) GFP of cells transfected with siRNA on day 1, 
viral vector on day 3 and measured on day 5. Cell viability measured with CellTiter-GLO and 
GFP. measured with SpectraMax plate reader. * cells are transfected only with viral vector not 












• Fixing and staining  
• Cell Number 
• Lipid Type and Concentration 
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• 96-well and 384-well plate 
Primary Assay 
• Human miRNA library 
• 384-well plate 
• Data analysis 
Validation Screen 
• Vector Titration Assay 
• 24-well and 12-well plates 
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Table 5-1: Scaled down conditions for viral vector transfection 
 
Table 5-2: Optimized conditions for double transfection in 384-well plate 
Step Reagent Concentration/Amount per well 
microRNA transfection microRNA 20 nM 
 Dharmafect4 0.03 µL 
 cell concentration 1,000 cells 
 Serum Free 
DMEM 20 µl including the lipid 
 20% FBS DMEM 20 µl including the cells 
 total volume 40 µL 
   
Viral Vector transfection DNAin 0.15 µl 
 Expression 
plasmid 80 ng 
 RD114 plasmid 40 ng 
 OptiMEM Remaining 
 total volume  20 µL 
   
Fixing/Staining Paraformaldehyde 16% 
 Hoechst 1:5000 dilution 
 PBS Remaining 



















100 mm 7854 10 9 4.5 1.5 40.5 1.5
24 well 200 0.5 0.23 0.11 0.04 1.03 0.04
96 well 32 0.1 0.04 0.02 0.01 0.17 0.01
384 well ** 5.6 0.04 0.006 0.003 0.001 0.029 0.001
384 well 
scaled by 




** viral vector transfection worked better after microRNA transfection in larger volume of  
optimem
* initially scaled by surface area, then realized should have scaled by volume
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Supplemental Figure S 5-1: RD114-GFP envelop protein plasmid map.  









Chapter 6 Conclusions and future work 
6.1 Final Thoughts 
The goal of this dissertation was to develop methods to improve recombinant protein expression 
and gamma retroviral vector production in mammalian cells using both intrinsic and extrinsic 
strategies. The previous chapters of this dissertation have demonstrated several strategies for 
improving both protein and retroviral vector production including identification of microRNA 
target genes, stable cell lines by overexpression of microRNA and by CRISPR knockout, 
perfusion bioreactors with microcarriers and the design of a high throughput non-coding RNA 
screen.  
The first approach, introduced a novel method of identifying gene targets of microRNAs. This 
made use of the combination of a microarray analysis, an siRNA screen, and predicted targets. 
The method was confirmed by the identification and verification of HIPK1 as a target of mir-22-
3p. Building on this approach, after identification of a target gene, stable cell lines were then 
created that either overexpressed mir-22 or had HIPK1 knocked out with CRISPR/Cas9 to 
compare protein expression improvement. This work demonstrates two good methods of 
producing a high expressing cell line for production purposes with the CRISPR/Cas9 clone 
having a larger improvement. Adapting the cell lines to anchorage independent culture provides 
the opportunity to scale up cells for use in an industrial application.  
Since adoptive T-cell therapy is a rapidly advancing field in the treatment of cancer, being able to 
supply enough T-cells for the growing number of patients is critical. The ability to produce 
enough viral vector could create a bottle-neck delaying T-cell production. To scale up viral vector 
production, a suspension-like culture was developed for the attachment dependent PG13 cells. By 
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using microcarriers in a continuous perfusion bioreactor system, a steady-state-like environment 
was created for the cells enabling production of a similar titer in a smaller footprint and allowing 
for scale-up possibilities, widening the neck of the bottle for vector production. 
Tying together the non-coding RNA cell engineering strategies from the first three chapters with 
the retroviral vector work from the fourth chapter, a non-coding RNA screen was designed with 
the intention of identifying specific microRNA and siRNA that will improve retroviral vector 
production for adoptive T-cell therapy.  
6.2 Future Work 
Continuation and expansion of the work detailed in this dissertation is currently underway. The 
RNAi screen designed in chapter five is currently being used to implement a microRNA screen 
for retroviral vectors for adoptive T-cell therapy. Once this has been validated, this may be 
extended to a genome wide siRNA screen for retroviral vectors. Since lentiviral vectors are also 
becoming more popular in adoptive T-cell therapy, small modifications to the design should be 
easy to implement and the siRNA screen should be easily translatable to the lentiviral vector 
system.  
These screens will produce many candidates for follow up studies. Since chapter three indicated it 
is likely more advantageous to pursue a CRISPR knockout than a microRNA overexpression, 
candidates from the genome wide siRNA screen would be a good place to begin, however 
CRISPR knockouts of microRNAs give an opportunity to explore the other side of the microRNA 
screen as well. A good target gene or microRNA could be stably knocked out or over-expressed, 
creating a high-producing retroviral or lentiviral packaging cell line.  
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In addition, concurrently the idea of perfusion systems is making enormous strides in industrial 
settings. There is a lot of opportunity for optimization of the continuous perfusion bioreactor 
system with microcarriers. Chapter four demonstrated the feasibility of producing retroviral 
vectors on microcarriers in a bioreactor system but did not thoroughly explore the many 
opportunities for improving the system such as scaling up, media formulation, perfusion rate, 
bioreactor conditions. To this end, many of the retroviral vectors and lentiviral vectors are 
currently produced in inefficient anchorage dependent transient or anchorage dependent stable 
packaging cell lines. If combined with the higher producing cell line achieved from the high 
throughput screen, this could have huge potential. With adoptive T-cell therapy and gene therapy 
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